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Abstract 
In 2015, the National Heart Foundation of Australia (NHFA) and the Cardiac Society of Australia and New 
Zealand (CSANZ) undertook a survey of emerging issues in cardiovascular disease. The goal was to 
prioritise clinical conditions that would benefit from locally developed contemporary guidelines. Individual 
diseases were evaluated according to burden of disease, the existence of treatment gaps, an evolving 
therapeutic landscape, evidence of inequity and the existence of local treatment guidelines. Atrial 
fibrillation (AF) scored highly in each of these categories. Specifically, AF was recognised as a 
burdensome condition with increasing prevalence, where large numbers of patients are not treated with 
anticoagulation, despite the clear benefit of this therapy in stroke prevention. Other factors relevant to AF 
were: 
• the relatively recent availability of non-vitamin K oral anticoagulants (NOACs), with a 
rapidly evolving evidence base guiding their use; 
• variation and uncertainty about best practice use of antiarrhythmic drugs 
• increasing availability of AF ablative procedures; 
• an increasing prevalence of AF in older people and Aboriginal and Torres Strait Islander 
peoples. 
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1. Rationale for These Guidelines
In 2015, the National Heart Foundation of Australia (NHFA)
and the Cardiac Society of Australia and New Zealand
(CSANZ) undertook a survey of emerging issues in cardio-
vascular disease. The goal was to prioritise clinical conditions
that would benefit from locally developed contemporary
guidelines. Individual diseases were evaluated according
to burden of disease, the existence of treatment gaps, an
evolving therapeutic landscape, evidence of inequity and
the existence of local treatment guidelines. Atrial fibrillation
(AF) scored highly in each of these categories. Specifically,
AF was recognised as a burdensome condition with increas-
ing prevalence, where large numbers of patients are not
treated with anticoagulation, despite the clear benefit of this
therapy in stroke prevention. Other factors relevant to AF
were:
 the relatively recent availability of non-vitamin K oral
anticoagulants (NOACs), with a rapidly evolving evidence
base guiding their use;
 variation and uncertainty about best practice use of anti-
arrhythmic drugs
 increasing availability of AF ablative procedures;
 an increasing prevalence of AF in older people and Aborig-
inal and Torres Strait Islander peoples.
International guidelines on the diagnosis and management
of AF are available [1,2], but these often differ from each
*Corresponding author. Email: briegster@gmail.com
1The AF writing group would like to specifically acknowledge Associate Professor Huyen Tran MBBS (Hons) Master Clin Epi FRACP FRCPA. The ‘‘National Heart
Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial
Fibrillation 2018” have been jointly developed by the Heart Foundation and the Cardiac Society of Australia and New Zealand. The Heart Foundation and the
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other with regards to individual recommendations, and no
such guidelines had been developed specific to the Austra-
lian population. Therefore, NHFA and CSANZ resolved to
produce Australian guidelines for AF.
These clinical guidelines have been developed to assist
Australian practitioners in the management of adult
patients with AF. They are intended to be used by practising
clinicians across all disciplines caring for such patients.
Some of the core recommendations of this document
have been informed by existing international guidelines,
including the 2016 European Society of Cardiology Guide-
lines for the management of atrial fibrillation [1], which
were developed in collaboration with the European Associ-
ation for Cardio-Thoracic Surgery, and the 2014 American
Heart Association/American College of Cardiology/Heart
Rhythm Society Guideline for the management of patients
with atrial fibrillation [2]. However, these Australian guide-
lines provide a focus on local practice and include some
updated recommendations reflecting more recent evidence
generation.
Recommendation GRADE quality of
evidence
GRADE strength of
recommendation
Screening and prevention—screening for silent atrial fibrillation (AF)
Opportunistic point-of-care screening in the clinic or community should be
conducted in people aged 65 years or more.
Moderate Strong
Screening for asymptomatic AF in patients with pacemakers and implanted devices
Pacemakers and defibrillators should be interrogated regularly for atrial high-
rate episodes (AHREs), and should be confirmed by atrial electrocardiogram
(EGM) to be AF.
Moderate Strong
Screening for AF in patients with embolic stroke of uncertain source (ESUS)
For patients with ESUS, longer term ECG monitoring (external or implantable)
should be used.
Moderate Strong
Diagnostic work up
A 12-lead electrocardiogram (ECG) is recommended for all patients with AF. Low Strong
A transthoracic echocardiogram should be performed in all patients with
newly diagnosed AF.
Low Strong
A thyroid stimulating hormone (TSH) test should be undertaken in
patients with newly diagnosed AF but should be delayed in acutely ill
patients.
Moderate Strong
Detection and management of risk factors and concomitant diseases
Intercurrent risk factors and comorbidities—including hypertension, diabetes,
heart failure, valvular heart disease and alcohol excess—should be identified
and their management considered an important component of treatment in
patients with AF.
Low Strong
Intensive management of weight—to a target of greater than or equal to
10% body weight loss, aiming for a body mass index (BMI) below 27—and
concomitant management of associated cardiovascular risk factors to
target levels should be performed in overweight and obese individuals
with AF.
Moderate Strong
Screening (by polysomnography) and management of sleep apnoea is
recommended in individuals with recurrent symptomatic AF.
Moderate Strong
Exercise that improves aerobic capacity is recommended in individuals with
symptomatic AF, to reduce the AF burden.
Moderate Strong
Arrhythmia management—rhythm control versus rate control
A rhythm-control or a rate-control strategy should be selected, documented
and communicated for all AF patients, and this strategy should be reviewed
regularly.
Low Strong
2. Key Recommendations
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(continued).
Recommendation GRADE quality of
evidence
GRADE strength of
recommendation
Arrhythmia management—acute rate control
Beta adrenoceptor antagonists or non-dihydropyridine calcium channel
antagonists are recommended for acute control of the ventricular rate in
haemodynamically stable patients, although caution is needed if given
intravenously.
Low Strong
Amiodarone is recommended for acute control of the ventricular rate in
highly symptomatic AF patients, or in those with known left ventricular
systolic dysfunction, who are not unstable enough to require immediate
electrical cardioversion.
Low Strong
Digoxin may be considered to aid in acute control of ventricular rate either as
add-on therapy to beta adrenoceptor antagonists or non-dihydropyridine
calcium channel antagonists, or as stand alone therapy if these agents and
amiodarone are contraindicated.
Low Weak
Arrhythmia management—long-term rate control
Beta adrenoceptor antagonists, digoxin and non-dihydropyridine calcium
channel antagonists should be the first-line agents used for long-term control
of the ventricular rate.
Moderate Strong
Digoxin can be considered for control of the ventricular rate in patients with
suboptimal rate control on, or with contraindications to, first-line agents.
Low Weak
When digoxin is used, serum concentration should be monitored, with the
goal of maintaining levels of <1.2 ng/mL.
Moderate Strong
Calcium channel antagonists should be avoided in patients with left
ventricular systolic dysfunction (ejection fraction <40%).
Low Strong
Amiodarone should not be administered as a first-line agent for chronic rate
control, given its toxicity profile.
Low Strong
Membrane-active antiarrhythmic agents (e.g. sotalol or flecainide) should not
be used in patients managed with a rate-control strategy.
Low Strong
Documentation of the adequacy of ventricular rate control (<110 beats per
minute [bpm]) at rest and with moderate exertion should be performed at
regular intervals in asymptomatic patients without heart failure.
Moderate Strong
Regular clinical surveillance for emergent cardiomyopathy or overt heart
failure should be performed during long-term follow-up because heart failure
may develop even in the presence of apparently adequate ventricular rate
control.
Low Strong
If pharmacological rate control fails, catheter ablation of the AV node should
be considered after a permanent pacing device has been implanted.
Moderate Strong
Arrhythmia management—acute rhythm control
Electrical cardioversion should be performed urgently in haemodynamically
unstable patients with AF.
Low Strong
Electrical cardioversion can be considered—either as a first-line option or
when pharmacological rhythm control fails—in haemodynamically stable
patients, after consideration of thromboembolic risk
Low Strong
Flecainide can be considered for rapid conversion to sinus rhythm, either
intravenously or orally, in patients without left ventricular systolic
dysfunction, moderate left ventricular hypertrophy, or coronary artery disease,
after consideration of thromboembolic risk.
Moderate Strong
AV nodal blocking medication is recommended for patients treated with
flecainide.
Low Strong
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(continued).
Recommendation GRADE quality of
evidence
GRADE strength of
recommendation
Amiodarone administered intravenously may be considered for delayed
conversion to sinus rhythm in patients with structural heart disease, including
patients with heart failure and coronary artery disease.
Moderate Strong
Arrhythmia management—long-term rhythm control
Flecainide can be considered in the maintenance of sinus rhythm in patients
without left ventricular systolic dysfunction, moderate left ventricular
hypertrophy or coronary artery disease.
High Strong
AV nodal blocking medication is recommended for patients treated with
flecainide.
Low Strong
Amiodarone can be considered for maintenance of sinus rhythm as a second-
line agent or as a first-line agent in patients with left ventricular systolic
dysfunction, moderate left ventricular hypertrophy or coronary artery disease.
High Strong
Sotalol may be considered for maintenance of sinus rhythm but requires close
monitoring of QT interval.
High Strong
Beta adrenoceptor antagonists may be considered for the maintenance of sinus
rhythm.
Moderate Weak
Arrhythmia management—percutaneous catheter AF ablation
Catheter ablation should be considered for symptomatic paroxysmal or
persistent AF refractory or intolerant to at least one Class I or III
antiarrhythmic medication.
High Strong
Catheter ablation can be considered for symptomatic paroxysmal or persistent
AF before initiation of antiarrhythmic therapy.
Moderate Strong
Catheter ablation can be considered for symptomatic paroxysmal or persistent
AF in selected patients with heart failure with reduced ejection fraction.
Moderate Strong
Arrhythmia management—surgical management of AF in the context of concomitant cardiac surgery
Surgical ablation of AF to restore sinus rhythm in the context of concomitant
cardiac surgery may be considered for patients with symptomatic paroxysmal,
persistent or long-standing persistent AF.
Moderate Strong
Arrhythmia management—stand-alone surgical or hybrid management of AF
Stand-alone surgical or hybrid ablation of AF can be considered for patients
with symptomatic paroxysmal, persistent or long-standing persistent AF that
is refractory, or intolerant to at least one Class I or III antiarrhythmic
medication, or where there has been failed percutaneous ablation, or where
the likelihood of successful percutaneous ablation is considered low.
Low Weak
Stroke prevention—predicting stroke risk
The CHA2DS2-VA score—the sexless CHA2DS2-VASc score—is recommended
for predicting stroke risk in AF.
Moderate Strong
The CHA2DS2-VA score should be re-evaluated yearly in low-risk patients
who are not anticoagulated.
Low Strong
Stroke prevention—prediction and minimisation of bleeding risk
Reversible bleeding factors should be identified and corrected in AF patients
for whom anticoagulation is indicated.
Low Strong
Stroke prevention—anticoagulation
Oral anticoagulation therapy to prevent stroke and systemic embolism is
recommended in patients with non-valvular AF (N-VAF) whose CHA2DS2-VA
score is 2 or more, unless there are contraindications to anticoagulation.
High Strong
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(continued).
Recommendation GRADE quality of
evidence
GRADE strength of
recommendation
Oral anticoagulation therapy to prevent stroke and systemic embolism should
be considered in patients with N-VAF whose CHA2DS2-VA score is 1.
Moderate Strong
Oral anticoagulation therapy to prevent thromboembolism and systemic
embolism is not recommended in patients with N-VAF whose CHA2DS2-VA
score is 0.
Moderate Weak
In asymptomatic patients with atrial lead pacemakers, anticoagulation should
be considered in device-detected and EGM-confirmed AF of 24 hours or more
in patients with a CHA2DS2-VA score of 2 or more.
Moderate Strong
When oral anticoagulation is initiated in a patient with N-VAF, a non-vitamin
K oral anticoagulant (NOAC)—apixaban, dabigatran or rivaroxaban—is
recommended in preference to warfarin.
Moderate Strong
Warfarin is recommended and NOACs should not be used in patients with
valvular AF (mechanical heart valves or moderate to severe mitral stenosis).
Moderate Strong
Antiplatelet therapy is not recommended for stroke prevention in N-VAF
patients, regardless of stroke risk.
Moderate Strong
Point-of-care international normalised ratio (INR) measurement is
recommended in the primary care management of patients receiving warfarin.
Moderate Strong
Stroke prevention—management of bleeding
Symptomatic treatment with fluid replacement or blood transfusion should be
initiated for all patients with moderate to severe bleeding while treatment of
the cause is addressed
Low Strong
Factor replacement therapy with prothrombin complex concentrates (PCCs)
can be considered for patients taking warfarin or specific factor Xa inhibitors
with life threatening bleeding or those requiring emergency surgery.
Low Weak
Idarucizumab is recommended for patients taking dabigatran who experience
life-threatening bleeding or require emergency surgery.
Low Strong
Anticoagulant therapy should be recommenced after bleeding has been
addressed and when the stroke risk is believed to exceed the risk of further
bleeding.
Low Strong
Stroke prevention—combining oral anticoagulants (OAC) and antiplatelet agent
Careful assessment of the bleeding and ischaemic risks (i.e. stroke, new or
recurrent cardiac ischaemia or infarction, and stent thrombosis) should be
undertaken for patients with AF who have a long-term requirement for
anticoagulation for stroke prevention and require dual antiplatelet therapy
(DAPT) after acute coronary syndrome (ACS) or stent implantation (or both).
Low Strong
Duration of triple therapy (aspirin, P2Y12 inhibitor and OAC) should be as
short as possible to minimise bleeding, while ensuring coverage of the initial
period of high risk of stent thrombosis and/or recurrent coronary ischaemia.
Moderate Strong
Where DAPT is required in combination with OAC, low-dose aspirin (100 mg)
and clopidogrel (75 mg) are recommended.
Ticagrelor and prasugrel are not recommended in this situation.
Low Strong
Where OAC is used for AF, discontinuation of antiplatelet therapy should be
considered 12 months after stent implantation, ACS, or both, with
continuation of OAC alone.
Low Weak
Anticoagulation in special situations—chronic kidney disease (CKD)
The decision to use anticoagulants in patients with AF and severe CKD
(creatinine clearance [CrCl] <30 mL/min) should be individualised because
there are no prospective data showing benefit in this population.
Low Strong
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Recommendation GRADE quality of
evidence
GRADE strength of
recommendation
Warfarin should be used if an AF patient with severe CKD requires
anticoagulant therapy.
Low Strong
Anticoagulation in special situations—bridging in anticoagulated patients requiring surgical procedures
Bridging with low molecular weight heparin (LMWH) or unfractionated
heparin (UFH) is not necessary for warfarin treated patients at low to
moderate risk of stroke undergoing planned surgical intervention.
Moderate Strong
Bridging with LMWH or UFH is not recommended for NOAC-treated
patients.
Low Strong
Bridging with LMWH or UFH is indicated for patients at very high risk of
stroke (e.g. warfarin-treated patients with mitral mechanical prosthetic heart
valves) undergoing planned surgical intervention.
Moderate Strong
Anticoagulation in special situations—cardioversion
Anticoagulation is recommended at the time of electrical or pharmacological
cardioversion, and for at least four weeks post-procedurally.
Low Strong
Anticoagulation for three weeks or a transoesophageal echocardiogram (to
document absence of left atrial [LA] thrombus) is recommended before
cardioversion in patients with more than 48 hours or an uncertain duration of
AF.
Low Strong
Anticoagulation in special situations—catheter ablation
Uninterrupted oral anticoagulation is recommended for patients undergoing
catheter ablation.
Moderate Strong
Stroke prevention—left atrial appendage (LAA) occlusion and exclusion
LAA occlusion may be considered for stroke prevention in patients with N-
VAF at moderate to high risk of stroke and with contraindications to oral
anticoagulation therapy.
Low Strong
Surgical occlusion or exclusion of the LAA may be considered for stroke
prevention in patients with AF undergoing cardiac surgery.
Moderate Strong
Secondary stroke prevention
Early initiation of anticoagulants in the first few days after an ischaemic stroke
is not recommended because of the risk of haemorrhage or haemorrhagic
transformation of infarction.
High Strong
For ischaemic stroke patients, the decision to begin OAC can be delayed for
two weeks but should be made before discharge.
Very low Weak
Early commencement of anticoagulants may be considered after transient
ischaemic attack (TIA) or in mild stroke where the risk of haemorrhage is
determined to be low.
Low Weak
Integrated management
An integrated care approach is recommended; such an approach aims to
provide patient-centred comprehensive treatment delivered by a
multidisciplinary team.
High Strong
Targeted patient education is recommended throughout the continuum of AF
management.
High Strong
Shared decision-making should consider patients’ beliefs, values and
preferences, with a goal of empowering patients to undertake self-
management.
Moderate Strong
Treatment goals should be developed in partnership with patients, and
communicated with all members of the multidisciplinary team.
Low Strong
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3. Preamble
3.1. Epidemiology of Atrial Fibrillation
AF is the most common recurrent arrhythmia faced in clinical
practice, and it causes substantial morbidity and mortality
[3–5]. Current estimates of AF prevalence in developed coun-
tries such as Australia range from 2% to 4%, and there is a
steep gradient with increasing age [4,6]. However, true prev-
alence is underestimated because subclinical AF is frequent
[7]. This can be a challenge for treating clinicians, because
adverse consequences of AF (e.g., a stroke) may occur before
AF is diagnosed. Apart from age, the prevalence of AF is
influenced by risk factors and comorbidities such as hyper-
tension, heart failure, coronary artery disease, valvular heart
disease, obesity, diabetes, and chronic kidney disease (CKD)
[4,6]. It is not surprising that Aboriginal and Torres Strait
Islander peoples have a higher incidence of AF and subse-
quent mortality attributable to their greater burden of car-
diovascular disease [8]. In Australia, prevalent AF cases in
people aged 55 years or more are projected to double over the
next two decades as a result of an ageing population and
improved survival from contributory diseases [9]. Future
prevalence of AF will also be affected by better detection
of AF and by a changing pattern of risk factors such as
obesity.
AF is independently associated with an increased long-
term risk of stroke, heart failure and all-cause death [3–5],
and often leads to an impaired quality of life [10]. The risk
of dying from stroke can largely be mitigated by oral
anticoagulants (OACs), but all-cause mortality and deaths
from complications such as heart failure remain high,
despite guideline-adherent treatment [3,6]. The concomitant
diseases that contribute most to all-cause mortality are not
thromboembolic [3], indicating the need for a comprehensive
care approach to reduce overall mortality in AF-affected
patients [11].
From a public health perspective, AF imposes a large and
growing burden on healthcare resources, with hospitalisa-
tions being the major cost driver [12]. Between 10% and 30%
of patients with AF are admitted to hospital each year for
cardiovascular and non-cardiovascular causes [13]. A study
showed that the total number of AF hospitalisations in
Australia was increasing by 6% per year over a 15-year
period, which was greater than that for other cardiovascular
conditions [14]. Hence, the societal and healthcare costs of AF
will continue to escalate unless AF and its risk factors and
complications are prevented and treated effectively.
3.2. The Process of Developing the 2018
Atrial Fibrillation Guidelines
These clinical guidelines for the management of AF seek to
provide guidance regarding the clinical care of patients with
AF. This is the first Australian guideline on this topic.
In late 2016, a partnership was formed between the NHFA
and the Cardiac Society of Australia and New Zealand
(CSANZ) to develop the guidelines, with the NHFA as the
lead organisation. Clinical committees of both organisations
were approached for advice regarding the content (scope)
and development process for the guideline.
Acting on advice from the NHFA internal clinical advisory
committees, members were approached to be in the working
group, according to expertise.
Based on the determined scope, guideline writing groups
were established to cover the following topics: screening and
prevention, arrhythmia management, and stroke prevention.
For each writing group, a primary writer was appointed by
group consensus, on the basis of expertise and previous
experience in guideline development. The other members
of the writing groups comprised members with recognised
expertise, from stakeholder groups, and the clinical commu-
nity, and included a consumer representative. The writing
groups met on several occasions to discuss the content of the
guideline during the development process.
A reference group was established comprising appointed
representatives of key stakeholder organisations with
national relevance in the provision of AF care in Australia.
The key roles of the group were to review and provide input
into the scope of the guidelines and the questions being
(continued).
Recommendation GRADE quality of
evidence
GRADE strength of
recommendation
eHealth tools and resources should be used by patients and health
professionals, to support the integrated management of AF.
High Strong
All patients prescribed pharmacotherapy for the management of AF, including
core rhythm control and anticoagulation therapies, should have their
treatment adherence and persistence regularly monitored and supported using
accessible and patient-centred strategies.
Low Strong
ACS: acute coronary syndrome, AF: atrial fibrillation, AHRE: atrial high rate episode, AV: atrioventricular, BMI: body mass index, bpm: beats per minute, CKD:
chronic kidney disease, CrCl: creatinine clearance, DAPT: dual antiplatelet therapy, ECG: electrocardiogram, EGM: atrial electrocardiogram, GRADE: Grading of
Recommendations Assessment: Development and Evaluation, INR: international normalised ratio, LAA: left atrial appendage, LMWH: low-molecular-weight
heparin, NOAC: non-vitamin K oral anticoagulant, N-VAF: non-valvular AF, OAC: oral anticoagulant, PCC: prothrombin complex concentrate, TIA: transient
ischaemic attack, TSH: thyroid stimulating hormone, UFH: unfractionated heparin.
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submitted for literature review, draft guideline content and
recommendations, and facilitate implementation of the
guidelines.
The working group generated clinical questions to form
the basis of external literature searches in consultation with
the clinical expert committees of NHFA and CSANZ. Ques-
tions for external literature searches were prioritised accord-
ing to uniqueness to Australia, and to areas not covered in
recent European guidelines [1,15]. These questions were
reviewed and refined by the reference group, and by clinical
expert committees from NHFA and CSANZ. Appendix 1 lists
the questions proposed for the literature review.
The literature reviewer was appointed through an open
tender process in May 2017. The external literature review
was started in the second half of 2017 and completed in
December 2017. The evidence summaries generated by the
reviewer were reviewed and signed off by the working
group, and relevant content for the guideline was based
on these evidence summaries. At the same time, the writing
group members reviewed evidence and drafted content for
the topics (in the agreed scope) in addition to those sent for
external literature searches.
In February 2018, the reference group was consulted on the
first full draft of the guideline. A public consultation period
of 21 days was conducted in April 2018. Final approval by the
clinical committees and the Boards of the NHFA and CSANZ
and submission for journal publication was undertaken in
June 2018.
3.2.1. Conflicts of Interest Process
Conflicts of interest were considered within a framework of
both the relationship (direct or indirect) of the participating
individual to any third party with interest in the topic under
consideration within the guideline development process, and
the nature (financial and non-financial) of the potential con-
flict. All members of the working groups and reference group
were asked to declare all potential conflicts of interest and
these declarations were updated every 6 months and at each
meeting. All conflicts of interest were managed by the work-
ing group chair or primary writer. A summary of the conflicts
of interest and responses will be provided in the online
appendix at the time of publication, and a full description
of the governance process for the development of this guide-
line will be available on the NHFA website.
3.2.2. Development of Recommendations
In addition to reviews of published trials and systematic
reviews, guideline content was informed by other interna-
tional clinical guidelines and local clinical expertise. Grading
of Recommendations Assessment, Development, and Evalu-
ation (GRADE) methodology was used to evaluate the
strength of recommendations. The first step in this process
involved an evaluation of the quality of the evidence sup-
porting the recommendation. If guided by randomised clini-
cal trials (RCTs), the quality of evidence was initially
estimated as high; if guided by observational or lower-qual-
ity evidence, the quality was estimated as low. Following
this, estimates were refined through detailed evaluation of
the quality of the evidence. Factors that lowered quality
included risk of bias, heterogeneity, or inconsistency
between studies, indirectness, imprecision, and publication
bias. Factors that increased quality included large magnitude
of effect, all plausible residual confounding worked to reduce
the demonstrated effect and dose–response gradient. The
final evaluation of the quality of evidence supporting each
recommendation is reported in these guidelines. Following
this evaluation, the strength of recommendation for or
against an intervention was provided. This was determined
by considering the quality of evidence, balance between
benefits and harms, uncertainty or variability in patient val-
ues and preferences, and resource considerations. The
strength of the recommendation was graded as either ‘weak’
or ‘strong’. This methodology is increasingly being used by
guideline developers in Australia and worldwide.
Each of the final recommendations was reviewed and
refined by the writing groups and the reference group, with
final review and endorsement by the whole working group.
The definition of consensus was more than 80% agreement of
all members of the working group.
The ‘Rationale’ section under each recommendation pro-
vides a brief summary of the key evidence underpinning the
recommendation. Economic implications or other relevant
system factors are discussed in the ‘Resources and other
considerations’ sections, where appropriate.
For topics where there is a limited evidence base, but
where the writing group felt there were important practical
factors to be considered, comments are included in the
‘Practice advice’ sections of the guideline. Where medication
recommendations are provided in this guideline, clinicians
are advised to refer to additional resources such as the
Australian Medicines Handbook for relevant doses, contraindi-
cations, precautions, drug interactions, and adverse effects.
4. Screening and Prevention
4.1. Pathophysiology and Genetic Factors
4.1.1. Risk Factors and Atrial Fibrillation
Several conditions have been shown to result in AF, by
causing structural alteration of the myocardium, which cre-
ates the electrophysiological milieu for the maintenance of
AF. In the preclinical setting this has resulted in an increase in
interstitial fibrosis, alteration of gap-junctional proteins,
altered tissue refractoriness, conduction slowing, and
increase in the heterogeneity of conduction [16–19]. Interest-
ingly, a chronic obesity ovine model indicated that epicardial
fat infiltration of the adjacent atrial myocardium may form a
unique substrate in obesity [20], and studies of sleep apnoea
have highlighted the potentially dynamic nature of this sub-
strate [21]. Clinical studies have also confirmed these find-
ings with areas of low voltage (presumably indicative of loss
of atrial myocardium), slowed and heterogenous conduction
with regions of complex and fractionated electrograms dem-
onstrated in mitral stenosis [22], heart failure [23],
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hypertension [24], congenital heart disease (atrial septal
defects) [25,26], sinus node disease [27], and obesity [28].
These changes have also been observed in the atria of indi-
viduals with no identifiable risks for AF, considered to be
‘lone AF’, suggesting the presence of either unrecognised or
undertreated insult that continues to damage the atrial myo-
cardium [29]. Newer risk factors are likely to emerge that
contribute to the burden of AF in the community [30]. Risk
factors for AF are not only important determinants of the
development of AF, but also contribute to the associated
risks, particularly that of stroke.
4.1.2. Genetic Predisposition
Underlying the potential for these conditions to result in
atrial remodelling is the likelihood of a genetic predisposi-
tion. Increasingly, the contribution of a genetic predisposi-
tion is recognised. This should be considered as two entities:
channelopathies that are associated with a greater risk of AF
and genes that are more frequently seen in individuals with
AF, particularly when there is a strong family history. These
entities are discussed below.
Channelopathies
The channelopathies that are known to result in ventricular
arrhythmias are associated with an increased risk of AF,
presumably because the atrial myocardium carries the same
abnormalities. They include the long or short QT and Bru-
gada syndromes. The incidence of early onset AF (aged <50
years) is about 2% with genetically proven long QT syn-
drome (LQTS), which is significantly higher than the
expected incidence of AF in this age group in the absence
of LQTS (<0.1%) [31]. AF is the most common atrial arrhyth-
mia in Brugada syndrome, with a reported incidence of 6%–
53% [32,33]. The SCN5A gene, which is one of the common
mutations responsible for Brugada syndrome, is also a com-
mon mutation detected in familial AF. Often, these are
young patients who present with isolated AF, and the treat-
ing clinician needs to be alert to the potential for harbouring
an underlying channelopathy.
Recognition of these conditions is particularly important in
the choice of antiarrhythmic drugs for these individuals.
Sotalol may unmask LQTS with the potential for pro-arrhyth-
mia. Flecainide potentially unmasks the Brugada syndrome,
with the risk of arrhythmia or presenting with sinus arrest in
the context of associated SCN5A gene defects. We strongly
recommend scrutiny of the family history and ECG in all
patients, but particularly in the young, with targeted inves-
tigations as appropriate.
Familial Atrial Fibrillation
Families with a high prevalence of AF have been observed and
reported in the literature since the 1950s [34,35]. From a large
national registry with more than 90 million person-years fol-
low-up, and close to 10,000 patients with lone AF, the incident
risk ratios for lone AF given an affected first-degree or second-
degree relative were 3.48 and 1.64, respectively [36]. The risk of
AF was even higher in the younger members (aged <40 years)
of the families of the patients with lone AF [36]. The Framing-
ham Heart Study showed a 26.8% prevalence of familial AF,
and the prevalence of premature familial AF in the young
participants was 7.9% [37]. Even after adjusting for modifiable
risk factors for AF (i.e. sleep apnoea and obesity) the familial
tendency of AF remains a relatively significant attributable risk
of AF [38]. Linkage analysis studies have implicated mutations
in potassium (KCNQ) and sodium (SCN5A) channels for
familial AF [39,40]. Unlike linkage analysis, genome-wide
studies have allowed testing of variants in genes or genetic
regionspreviouslynotsuspectedinAFpathogenesis. Themost
significantly associated variant associated with AF is the
paired-like homeodomain 2 transcription factor (PITX2) on
chromosome 4q25 locus [41]. It is becoming apparent that these
variants may also be important determinants of treatment
outcomes [42,43].
4.1.3. Electrophysiological Mechanisms of Atrial
Fibrillation
The development of AF depends on the critical interaction of
various triggers with the atrial substrate for AF [44]. These
triggers are increasingly recognised as coming from within
the venous structures appended to the atria. Less frequently,
they have been described from other atrial sources. Much less
is known about the mechanisms that maintain AF. These
mechanisms have included theories of the multiple wavelet
re-entry, focal drivers or rotors, and endo-epicardial re-entry.
The contribution of each of these mechanisms, and the ability
to identify them in the clinical setting, continues to be an
important area of investigation.
4.2. Definition of Non-valvular Atrial
Fibrillation
This guideline encompasses both N-VAF and valvular AF.
N-VAF refers to AF in the absence of moderate to severe
mitral stenosis or mechanical heart valve [45].
4.3. Classification
In many patients, AF progresses from short paroxysmal
episodes to more frequent and persistent attacks, and then
often to permanent AF. However, progression can be miti-
gated by aggressive targeting of modifiable cardiovascular
risk factors [46]. Four main clinical patterns of AF have been
described, based on duration and termination of AF episodes
(see Table 1) [15].
While classifying patterns of AF has some clinical value, it
is often inaccurate and underestimates the temporal persis-
tence of AF captured by continuous ECG monitoring [47].
Furthermore, the independent role of these AF patterns for
distinguishing the response to therapies, such as antiarrhyth-
mic drugs, and for prediction of stroke risk and survival is
uncertain [48].
4.4. Diagnosis and Timely Detection
The diagnosis of atrial fibrillation requires rhythm documen-
tation using an ECG showing absolutely irregular RR inter-
vals and no discernible distinct P waves. By accepted
convention, an episode lasting at least 30 seconds is
diagnostic.
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4.4.1. Screening for Silent Atrial Fibrillation
Recommendation: Opportunistic point-of-care screening
in the clinic or community should be conducted in people
aged 65 years or more.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: There is strong epidemiological evidence that
previously unknown AF is associated with about 10% of
all ischaemic strokes [49,50]. Evidence from systematic
reviews indicates that 1.4% of patients in community or
practice situations aged 65 years or more will have unknown
asymptomatic AF on single time point screening of pulse
ECG [7]. Screening using patient-activated handheld ECG
devices twice daily over 2 weeks in those aged 75 or 76 years
found 3% with unknown AF [51]. Most of those found with
unknown AF by screening will be at high enough risk of
stroke score to justify treatment with an OAC based on net
clinical benefit. Thus, AF meets the justification for screening,
which is to find patients with unknown asymptomatic AF at
high-enough risk of stroke to result in a reduction in stroke
burden from combined screening and treatment [50].
The actual risk of stroke and death in people with screen-
detected AF is unknown, and determination of this risk would
require an unethical natural history study withholding treat-
ment. The closest approximation of risk is patients with AF
detected incidentally in the absence of symptoms [50]. Several
cohortstudieshaveshown that such patients areat similar ifnot
greater risk than patients with a symptomatic presentation [52–
57]. In one of these cohort studies [54,58], the effect of anticoag-
ulantversusnoanticoagulant treatment wassimilar to thatseen
in the meta-analysis of controlled studies of anticoagulants in
AF. Several cost–effectiveness simulations [50,59–68], based on
screening study data, have suggested that screening for AF is
cost effective for both increasing quality-adjusted life years
(QALYs) and reducing stroke. Additionally, opportunistic case
finding (opportunistic screening) was found to be more cost
effective than systematic screening in an RCT [60,61].
Benefits and harms: The benefits (stroke prevention or
reduction of death) and harms (major bleeding) of anticoag-
ulant treatment in screen-detected AF have been assumed to
be the same as for symptomatic AF. The potential harms of
screening include anxiety over a false diagnosis (which can
be minimised by screening using a handheld ECG with
immediate diagnosis), and an anticipated anxiety over the
diagnosis of AF in a person who previously had no illness.
The potential harms of not screening are strokes that may
occur because the condition is not diagnosed before stroke.
One large randomised outcome study of population system-
atic screening is due to report in August 2018 and may
resolve some of these questions [51].
Resources and other considerations: Opportunistic case
finding for AF should be recommended as standard practice
for patients aged 65 years or more, given the likely favourable
risk to benefit ratio of treating screen-detected AF; the consis-
tent finding of cost-effectiveness of health economic analyses
(including one using Australian costs) [63]; and the rate, ease,
and low cost of detection of AF by opportunistic screening in
the clinic demonstrable in Australian studies. If twice-daily,
30-second, patient-initiated ECG rhythm recordings are found
to be effective for stroke prevention, this may be a preferred
option for both systematic and opportunistic screening.
Practice advice: Opportunistic annual screening for AF in
general practice in patients aged 65 years or more is easily
accomplished by pulse palpation, followed by an ECG (if
irregular), or by an ECG rhythm strip using a handheld ECG.
This screening can be incorporated into standard consulta-
tions or undertaken by practice nurses during chronic care
consultations or immunisations. Devices that provide a
medical-quality ECG trace are preferred to pulse-taking or
pulse-based devices (i.e. photoplethysmography and blood
pressure oscillometry) for screening, because an ECG is
required to confirm the diagnosis.
4.4.2. Screening for Asymptomatic Atrial Fibrillation in
Patients with Pacemakers and Implanted Devices
Recommendation: Pacemakers and defibrillators should be
interrogated regularly for AHREs, and should be confirmed
by EGM to be AF.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Table 1 Patterns of atrial fibrillationa.
Paroxysmal AF Episodes that terminate spontaneously or are cardioverted within 7 days; may recur with variable frequency.
Persistent AF Episodes of continuous AF that last >7 days and do not self-terminate, including episodes that are cardioverted
after 7 days or more.
Long-standing
persistent AF
Continuous AF lasting for 1 year when it is decided to adopt a rhythm control strategy.
Permanent AF Applies when a decision has been made jointly by the physician and patient to accept the presence of AF and
stop further attempts to restore or maintain sinus rhythm. This represents clinical acceptance rather than an
inherent pathophysiological attribute of AF and, should a rhythm-control strategy be adopted, the arrhythmia
should be re-classified as ‘long-standing persistent AF’.
AF, atrial fibrillation.
aKirchhof P, et al. 2016. Eur Heart J 2016; 37 (38): 2893–2962. By permission of OUP on behalf of the ESC. This table is not included under the Creative Commons license of this
publication. © ESC 2016. All rights reserved. For permissions email journals.permissions@oup.com [15].
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Rationale: Implanted pacemakers, defibrillators and other
cardiac implanted electrical devices (CIEDs) with atrial
leads allow continuous monitoring of atrial rhythm and
identification of patients with AHREs. Implanted loop
recorders (also known as implanted cardiac monitors
[ICMs]) allow continuous examination of cardiac rhythm
and produce a single-lead ECG. AHREs or AF on ICMs are
usually defined as lasting longer than 5 or 6 minutes. Not all
automated AHRE detection in CIEDs or automated AF
detection in ICMs represent AF. The stroke risk in these
patients seems lower than the stroke risk in patients with
clinically diagnosed AF [69,70]. There is considerable debate
about the cut-off for duration of episode or AF daily burden
required before the risk is sufficient to justify anticoagula-
tion [69–73], with some recommending anticoagulation for a
daily burden of more than 5.5 hours, or a single episode
lasting more than 24 hours, in those with stroke risk scores
equivalent to the threshold for anticoagulation of patients
with clinical AF. There is an increasing consensus that
episodes of more than 24 hours denote a greater burden
of AF and may justify anticoagulation in at-risk patients
[74,75], though even this threshold is not excluded from the
Non-vitamin K Antagonist Oral Anticoagulants in Patients
with Atrial High Rate Episodes (NOAH-AFNET 6) trial [76],
indicating some equipoise. There is considerable uncer-
tainty about the prognosis and anticoagulant requirement
for episodes or AHREs with daily AHREs burden between
5.5 and 24 hours. Further data will be available when the
ongoing randomised studies NOAH-AFNET 6 [76] and
Apixaban for the Reduction of Thrombo-Embolism in
Patients with Device-detected sub-clinical Atrial Fibrillation
(ARTESiA) [77] are completed. Recommendations for anti-
coagulation in this guideline are provided and discussed in
Figure 1 and in Section 6.3.
Detection of AHREs on devices indicates a high risk of
subsequent development of clinical AF [69,70]. Patients with
pacemakers should be routinely interrogated for AHRE and,
if AHRE is detected, further assessment of stroke risk factors
and surveillance for development of clinical AF should be
performed [78]. It is uncertain what ECG surveillance should
be used, other than continued surveillance and interrogation
of implanted devices, or whether device telemetry with
remote monitoring is worthwhile [79].
Practice advice: For CIEDs with an atrial electrode, the
electrograms must be examined to ensure that an AHRE
actually represents AF and not another arrhythmia or arte-
fact. For ICMs, the output trace is essentially a single-lead
ECG rhythm strip, which needs to be examined to verify that
the arrhythmia is actually AF.
4.4.3. Screening for Atrial Fibrillation in Patients with
Embolic Stroke of Uncertain Source
Recommendation: For patients with ESUS, longer term
ECG monitoring (external or implantable) should be used.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Figure 1 Management of atrial high-rate episodes.
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Rationale: The detection of unrecognised paroxysmal AF in
patients with presumed embolic stroke presenting in sinus
rhythm with no history of AF may be important to reduce the
risk of recurrent stroke. Twenty-four-hour Holter monitoring
has been commonly used and is readily available, but a
substantial proportion of patients with paroxysmal AF are
not detected using this approach [80,81]. External rhythm
recording devices can be worn for up to 30 days, but data
from implanted devices show that a substantial proportion of
AF occurs beyond the first 30 days following an event.
Implantable loop recorders can provide up to 3 years of
continuous monitoring. Whilst there is some question about
the relevance of AF detected many months after the stroke to
the aetiology of the original event, late-detected AF does
remain a significant risk factor for subsequent stroke.
ESUS describes a subgroup of patients at theoretically
higher risk of silent paroxysmal AF and comprises a non-
lacunar infarct in the absence of significant proximal
cerebral vessel disease, no evidence of thrombus on an
echocardiogram, and no AF following at least 24 hours
of ECG monitoring. Whether empiric anticoagulation of
these patients improves outcomes compared to standard
care is being evaluated in ongoing randomised trials, one
of which (Rivaroxaban Versus Aspirin in Secondary Pre-
vention of Stroke and Prevention of Systemic Embolism in
Patients With Recent Embolic Stroke of Undetermined
Source—NAVIGATE ESUS) was recently prematurely
halted for futility. However, there is clear evidence that a
longer duration of monitoring is associated with higher
frequency of AF detection in patients with embolic stroke
of uncertain source [80,81]. When AF is detected and anti-
coagulation is commenced, the benefits for stroke preven-
tion in patients with previous stroke are well-established
(see Section 6.3.6).
Benefits and harms: The randomised Study of Continuous
Cardiac Monitoring to Assess Atrial Fibrillation After Cryp-
togenic Stroke (CRYSTAL AF) reported a significantly higher
rate of AF detection using the ILR compared with standard of
care at 6 months (hazard ratio [HR] = 6.4 (95% confidence
interval [CI]: 1.9–21.7), 12 months (HR = 7.3 (95% CI: 2.6–
20.8)), and 36 months (HR = 8.8 (95% CI: 3.5–22.2). Of those
detected with AF, 23/29 of cases (79%) were asymptomatic
over 12 months [82]. The risk of an adverse event associated
with ILR implantation is low.
Practical advice: This section aligns with recommenda-
tions in the Stroke Foundation Clinical Guidelines for Stroke
Management. Further details on management of this patient
cohort can be found in their online resource [83].
4.5. Diagnostic Work up
Recommendation: A 12-lead ECG is recommended for all
patients with AF.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Rationale: All patients with newly diagnosed AF require a
complete medical history and evaluation, focusing on the
following domains:
 haemodynamic stability or severe symptoms;
 presence of precipitating factors (e.g., sepsis, recent sur-
gery, thyrotoxicosis, electrolyte imbalance) and underly-
ing cardiovascular conditions;
 stroke risk and need for anticoagulation (see Section 6);
 heart rate and need for rate control (see Sections 5.1 and
5.2);
 symptom assessment and decision for rhythm control (see
Section 5.3).
A 12-lead ECG not only establishes the diagnosis of AF, it
also provides evidence of conduction defects, ischaemia, and
signs of structural heart disease.
Initial blood tests should include full blood count, electro-
lytes, and renal function, as well as tests of thyroid function
(see Section 4.5.1). Transthoracic echocardiography is also
recommended (see Section 4.5.2).
4.5.1. The Role of Electrolyte Assessment in Newly
Diagnosed Atrial Fibrillation
A strong recommendation has traditionally been made for
the assessment of electrolytes, despite the lack of high-quality
data from randomised trials. This is because of a general view
that the benefits of the assessment outweigh the risks, and
because of the physiological role of electrolytes in electrical
and mechanical actions of the body.
A diagnostic work up should include serum electrolytes,
including potassium, sodium, magnesium, and calcium,
which play a significant physiological role in the regulation
of the electrical and mechanical action of the heart.
Any abnormal concentration of these ions may result in
muscle contraction disorders, cardiac arrhythmias, and drug
interactions.
Acute presentations of AF may also require normalisation
of fluid balance and management of heart failure, which in
turn requires measurement of electrolytes for safe adminis-
tration of therapy.
4.5.2. Role of Echocardiography in Newly Diagnosed
Atrial Fibrillation
Recommendation: A transthoracic echocardiogram should
be performed in all patients with newly diagnosed AF.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Rationale: A transthoracic echocardiogram can assist patient
management by identifying valvular heart disease, and quan-
tifying left ventricle (LV) function and atrial size. Transthoracic
echocardiogram will yield data on some key parameters:
 mitral stenosis and regurgitation—both of these conditions
can lead to increased atrial size and hence AF; mitral
stenosis can also increase thromboembolic risk, and
NOACs are contraindicated in patients with moderate
or severe mitral stenosis;
 LA size and volume [84]—LA volume may be a stronger
predictor than LA size for predicting AF and stroke risk
[85];
 LV—moderate to severe LV systolic dysfunction leads to
a 2.5-fold increase in the risk of thromboembolism [86];
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reversible LV dysfunction may develop in patients with
uncontrolled AF (see Section 5.2).
Transoesophageal echocardiography (TOE) can be consid-
ered when findings might affect patient management,
primarily where electrical or pharmacological cardioversion
is indicated and the presence of thrombus may affect timing
(see Figure 2).
Resources and other considerations: No studies have been
found to indicate the yield or cost-effectiveness of this
Figure 2 Electrical cardioversion.
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investigation in Australian populations. In rural centres
where echocardiography may be limited, referral to a
regional centre is warranted.
4.5.3. Role of Thyroid Function Testing in Newly
Diagnosed Atrial Fibrillation
Recommendation: A TSH test should be undertaken in
patients with newly diagnosed AF but should be delayed
in acutely ill patients.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: AF is traditionally associated with hyperthyroid-
ism, but overt thyroid disease appears to be rare in people
presenting with AF, and yield of testing is low [87]. Making a
diagnosis of overt thyroid disease is also complicated by the
fact that any acute illness affects thyroid indices, and most
abnormal indices in hospital return to normal when repeated
after the resolution of the acute illness [88]. Hence, this
screening should be reserved for stable outpatients.
Subclinical hyperthyroidism due to various pathologies (e.
g., thyroid adenomas, multinodular goitre, Grave’s disease,
or thyroiditis) needs to be treated to avoid longer-term
sequelae of subclinical hyperthyroidism. Such sequelae
include low bone mineral density, heart failure, angina,
and progression to overt hyperthyroidism. It is unknown
whether treating subclinical hyperthyroidism prevents inci-
dent AF.
4.5.4. Detection and Management of Risk Factors and
Concomitant Diseases
Recommendation: Intercurrent risk factors and comorbid-
ities—including hypertension, diabetes, heart failure, val-
vular heart disease and alcohol excess—should be
identified and their management considered an important
component of treatment in patients with AF.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Intensive management of weight—to
a target of greater than or equal to 10% body weight loss,
aiming for a BMI below 27—and concomitant management
of associated cardiovascular risk factors to target levels
should be performed in overweight and obese individuals
with AF.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Screening (by polysomnography) and
management of sleep apnoea is recommended in individ-
uals with recurrent symptomatic AF.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Exercise that improves aerobic capac-
ity is recommended in individuals with symptomatic AF, to
reduce the AF burden.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: Cardiovascular risk factors are recognised con-
tributors to the development of AF [89]. Several of these risk
factors are well established; they include hypertension,
diabetes mellitus, and alcohol excess. In addition, several
cardiovascular conditions are associated with the develop-
ment of AF, including coronary artery disease, heart failure,
valvular disease, and sinus node disease.
The more risk factors that an individual has, the greater the
likelihood that a person will develop AF and more persistent
AF [90,91]. Cardiovascular risk factors are also an important
determinant of recurrence of AF when using a rhythm-con-
trol strategy [92–97].
More recently, studies have presented data on the treat-
ment of these risk factors in reducing the symptom burden
and increasing the likelihood of maintaining sinus rhythm in
patients with established AF [98–101]. This has led to the
concept that risk factor management represents the ‘fourth
pillar’ in AF management [15,89].
Management of Concomitant Disease in AF
Treating underlying disease state has been observed to
reduce incident AF, particularly in cohorts with heart failure
[102,103]. However, these conditions can also exacerbate the
risk of complications associated with AF; hence, their man-
agement is an important part of the management of individ-
uals with AF. The impact of management of these conditions
on AF itself has not been evaluated.
Treating Risk Factors in Isolation
Observational studies suggest that treating individual risk
factors may affect the maintenance of sinus rhythm in indi-
viduals with AF. For example, an increasing amount of data
suggests that treatment of sleep apnoea improves the main-
tenance of sinus rhythm in rhythm-control strategies [94,95].
However, data from RCTs are lacking.
Short-term randomised studies demonstrate some
improvements in reducing AF symptom burden. This has
been observed in a small randomised study that evaluated
the role of exercise intervention [104].
There are data that suggest that treatment of hypertension
has a role in the primary prevention of AF [102]. However,
regarding secondary prevention, the Substrate Modification
with Aggressive Blood Pressure Control (SMAC-AF) study
showed that aggressive management of hypertension in iso-
lation peri-ablation did not alter the maintenance of sinus
rhythm [105]. This experience highlights the limited value of
treating isolated risk factors in a disease such as AF, which
has multiple contributors in a given individual [106].
Detection and Management of Newer Risk Factors
With the burden of AF increasing at rates greater than those
predicted by known risk factors, there has been interest in
several newer risk factors [107], including obesity, sleep
apnoea, physical inactivity and prehypertension [30,108–
111]. These risk factors have now been demonstrated to result
in change to the atrial myocardium and remodelling that
favours the development and maintenance of AF [18–
20,24,112–114]. Several studies have characterised the atrial
substrate for arrhythmia in these conditions, and reported
similar findings to those seen with the various cardiac risk
factors [16,22,23,27].
Comprehensive and Aggressive Risk Factor Management
A study has demonstrated that physician-led intervention of
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weight and risk factor management in overweight and obese
patients led to a marked reduction in AF symptom burden,
and AF episode frequency and duration, and to an improve-
ment in quality of life in patients with paroxysmal AF [98].
The response is graded—the greater the weight loss, the
more the likelihood that the sinus rhythm will be maintained
[100]. Similar findings have been reported for physical activ-
ity levels [101]. In addition, in patients undergoing catheter
ablation, aggressive management of risk factors has been
associated with a significantly greater chance of remaining
in sinus rhythm [99].
Practice advice: The aggressive risk factor management
treatment targets used in the above studies included:
 weight loss of at least 10% or final BMI less than 27 kg/m2,
with avoidance of weight fluctuation. Target BMI or
weight in people aged over 75 years is unknown;
 exercise to improve aerobic capacity for up to
210 minutes/week;
 blood pressure of less than or equal to 130/80 mm Hg at
rest, and less than or equal to 200/100 mm Hg on exercise;
 maximal compliance with continuous positive airway
pressure (CPAP) therapy if the apnoea–hypopnea index
was equal to or greater than 15/hour;
 an HbA1c of less than or equal to 6.5%;
 lipid targets per overall cardiovascular risk profile;
 smoking cessation;
 limitation of alcohol consumption to less than or equal to
three standard drinks per week [46,115].
5. Arrhythmia Management
Recommendation: A rhythm-control or a rate-control strat-
egy should be selected, documented and communicated
for all AF patients, and this strategy should be reviewed
regularly.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
5.1. Acute Rate Control
Recommendation: Beta adrenoceptor antagonists or non-
dihydropyridine calcium channel antagonists are recom-
mended for acute control of the ventricular rate in haemo-
dynamically stable patients, although caution is needed if
given intravenously.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Amiodarone is recommended for
acute control of the ventricular rate in highly symptomatic
AF patients, or in those with known left ventricular systolic
dysfunction, who are not unstable enough to require imme-
diate electrical cardioversion.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Digoxin may be considered to aid in
acute control of ventricular rate either as add-on therapy to
beta adrenoceptor antagonists or non-dihydropyridine
calcium channel antagonists, or as stand-alone therapy if
these agents and amiodarone are contraindicated.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Weak.)
Rationale: Significant symptoms can result from acute epi-
sodes of new onset AF, and from breakthrough rapid epi-
sodes in those with an established diagnosis of AF. Less
commonly, in the acute setting, haemodynamic compromise
may also result from such episodes. When severe and life-
threatening, the latter situation calls for immediate electrical
cardioversion (see Table 2 and Figure 2). In any less-serious
circumstance, particularly while thromboembolic risk assess-
ment and management are being instituted, urgent rate con-
trol is the most effective option for alleviating symptoms.
Secondary causes of rapid ventricular response—including
sepsis, pulmonary embolism, and thyrotoxicosis—must be
excluded.
Effective options for immediate rate control include beta
adrenoceptor antagonists and non-dihydropyridine calcium
antagonists [116] (see Figure 3).Oral administration of these
agents may be sufficient in many situations, but this will be
associated with a longer time to onset of effect. A more rapid
onset of action may be seen with careful administration of
intravenous aliquots of metoprolol or esmolol. The only
intravenous rate-control calcium antagonist available in
Australia is verapamil, but it must be used with extreme
caution because of its strong negatively inotropic effect.
Digoxin may be considered in addition to the above agents,
but it has a delayed onset of action, may have a weak effect in
terms of rate control, and has a narrow therapeutic index.
Digoxin monotherapy may not result in effective rate control
[117].
In patients with marginal haemodynamic reserve, estab-
lished heart failure, or other significant structural heart dis-
ease, amiodarone may be the most effective (and only) rate-
control option. The initial mode of activity of amiodarone is
through both Class II and Class IV effects, and this results in
early effective slowing of atrioventricular (AV) conduction
[118]. Intravenous loading is usually preferred in the acute
situation; however, oral bioavailability is excellent and oral
loading may also be rapidly effective in some instances.
Table 2 Factors favouring a strategy of rhythm control
over rate control.
Patient preference
Highly symptomatic or physically active patients
Difficulty in achieving adequate rate control
LV dysfunction (mortality benefit)
Paroxysmal or early persistent AF
Absence of severe atrial enlargement
Acute AF
AF: atrial fibrillation, LV: left ventricle.
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Practice advice: If intravenous loading with amiodarone is
undertaken, chemical phlebitis can occur, necessitating high-
quality and preferably central venous access.
5.2. Long-term Rate Control
Recommendation: Beta adrenoceptor antagonists or non-
dihydropyridine calcium channel antagonists should be
the first-line agents used for long-term control of the ven-
tricular rate.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Digoxin can be considered for control
of the ventricular rate in patients with suboptimal rate
control on, or with contraindications to, first-line agents.
Figure 3 Acute rate control of atrial fibrillation with rapid ventricular response.
1226 D. Brieger et al.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Weak.)
Recommendation: When digoxin is used, serum concen-
tration should be monitored, with the goal of maintaining
levels of <1.2 ng/mL.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Calcium channel antagonists should
be avoided in patients with left ventricular systolic dys-
function (ejection fraction <40%).
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Amiodarone should not be adminis-
tered as a first-line agent for chronic rate control, given its
toxicity profile.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Membrane-active antiarrhythmic
agents (e.g., sotalol or flecainide) should not be used in
patients managed with a rate-control strategy.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Documentation of the adequacy of
ventricular rate control at (<110 bpm) at rest and with
moderate exertion should be performed at regular intervals
in asymptomatic patients without heart failure.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Regular clinical surveillance for emer-
gent cardiomyopathy or overt heart failure should be per-
formed during long-term follow-up because heart failure
may develop even in the presence of apparently adequate
ventricular rate control.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Rationale: There are few RCTs to guide treatment decisions
in AF rate control, and most recommendations are based on
observational data or expert consensus.
Clinical trials comparing rate-control and rhythm-control
strategies for managing AF with and without heart failure
were completed more than 10 years ago, and they failed to
demonstrate an improvement in prognosis with pharmaco-
logical rhythm control [119–124]. Large-scale RCTs compar-
ing rate control with contemporary (particularly non-
pharmacological) rhythm-control strategies are lacking.
One randomised trial—Rate Control Efficacy in Permanent
Atrial Fibrillation: A Comparison Between Lenient Versus
Strict Rate Control II (RACE II)—compared a lenient rate-
control target (<110 bpm resting ventricular rate) to a strict
rate target (<80 bpm resting and <110 bpm during moderate
exertion) in 614 patients with permanent AF [125]. No dif-
ference in the primary composite outcome was found, and
there was no benefit on symptoms with a strict rate-control
strategy. However, two-thirds of patients were asymptom-
atic at enrolment, and the lenient rate-control group had an
actual mean resting rate during the study of 85 bpm, only
10 bpm faster than the strict rate-control group.
A ventricular rate-control strategy is implemented by the
use of beta adrenoceptor antagonists, diltiazem or verapamil,
alone or in combination [126] (see Figure 4). Digoxin should
not generally be used alone because of its slow onset of action
in the acute situation and its weak effect in chronic rate
control, particularly during exertion [127]. However, digoxin
can be useful as a second-line agent or in combination with
beta blockers or calcium antagonists. There are conflicting
data on the association between all-cause mortality and
digoxin use in AF, with or without concomitant heart failure,
although this signal has generally not been seen in RCTs
[128]. In a recent observational analysis of patients antico-
agulated for atrial fibrillation, digoxin use was not associated
with an increase in mortality; however among patients taking
digoxin the risk of death was independently related to serum
digoxin concentration and was highest in patients with con-
centrations 1.2 ng/mL [129]. Verapamil and diltiazem
should not be used in the presence of left ventricular systolic
dysfunction because of their negative inotropic effect. Amio-
darone should be considered a last-line option for chronic
pharmacological rate control, given its toxicity profile. Mem-
brane-active rhythm-control agents (e.g., flecainide or sota-
lol) should not be used or continued in patients being started
on or transitioned to a rate-control strategy. This is because
the potential proarrhythmic side effects of these agents can-
not be justified when no active pursuit of sinus rhythm is
being made.
Practice advice: A rate-control strategy may be used in
preference to rhythm-control in patients with minimal symp-
toms or in those in whom attempts at maintaining sinus
rhythm are likely to be futile. Patients who have not
responded to a rhythm-control strategy may be managed
with rate control. In general, a rate-control strategy is not
useful for patients with symptomatic paroxysmal AF epi-
sodes; also, it should not be used in pregnancy or in the
special situation of pre-excited AF.
A growing amount of data demonstrates that apparently
adequate rate control may be associated with suboptimal
symptom control, and with attendant or progressive ventric-
ular systolic dysfunction. Hence, it is important that AF
patients being managed with a rate-control strategy are kept
under regular and close surveillance for any suggestion of
clinical decompensation, and for the potential development
of AF-related cardiomyopathy. Patients developing symp-
toms or signs of left ventricular dysfunction should be
referred for cardiology review and considered for echocar-
diography. However, there is no role for routine screening
echocardiography for detection of subclinical left ventricular
dysfunction in patients with atrial fibrillation.
Recommendation: If pharmacological rate control fails,
catheter ablation of the AV node should be considered after
a permanent pacing device has been implanted.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: Several small RCTs (all with <250 patients) have
compared medical rate control and catheter ablation of the
AV node in AF patients with heart failure. Despite limited
Australian Atrial Fibrillation Guidelines 2018 1227
sample size and significant heterogeneity, there was a con-
sistent tendency to AV node ablation patients having
improvements in symptomatic outcome, VO2 max, 6-minute
walk distance, heart failure admissions, ejection fraction, and
mortality (where assessed) [130–133].
For patients who fail medical rate control and for whom AF
ablation is not deemed appropriate, permanent pacemaker
implantation followed by catheter ablation of the AV node
offers a permanent solution to the problem of rapid ventric-
ular response in AF [134–136] (see Figure 4). One multicentre
prospective study, the Ablate and Pace Trial, showed signifi-
cant improvements in quality of life and left ventricular
systolic function in a group of 156 medically refractory
patients [135,136]. There is no indication of impaired long-
Figure 4 Chronic rate control of atrial fibrillation with rapid ventricular response.
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term survival with AV node ablation compared with phar-
macological rate control [137].
Practice advice: When planning AV node ablation, the
optimal choice of pacemaker type and pacing configuration
is still unclear. The limited data available from randomised
trials suggests an advantage for biventricular pacing in
improving functional capacity and preserving ejection frac-
tion compared with right ventricular pacing.
5.3. Rhythm Control
5.3.1. Acute Rhythm Control
Recommendation: Electrical cardioversion should be per-
formed urgently in haemodynamically unstable patients
with AF.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Electrical cardioversion can be consid-
ered—either as a first-line option or when pharmacological
rhythm control fails—in haemodynamically stable
patients, after consideration of thromboembolic risk.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Flecainide can be considered for rapid
conversion to sinus rhythm, either intravenously or orally,
in patients without left ventricular systolic dysfunction,
moderate left ventricular hypertrophy or coronary artery
disease, after consideration of thromboembolic risk.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: AV nodal blocking medication is rec-
ommended for patients treated with flecainide.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Amiodarone administered intrave-
nously may be considered for delayed conversion to sinus
rhythm in patients with structural heart disease, including
patients with heart failure and coronary artery disease.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: Patients with haemodynamic instability require
urgent electrical cardioversion (see Table 2 and Figure 2). In
haemodynamically stable patients, acute rhythm rather than
rate control can be considered if symptoms are unacceptable or
inpatientsexperiencingtheirfirstepisodeofAF.There isa high
spontaneous reversion rate to sinus rhythm for new-onset AF
within 48 hours, so while pharmacological cardioversion can
be considered, a ‘wait and watch’ approach with rate control
may be reasonable in a mildly symptomatic patient.
Flecainide or amiodarone are the recommended drugs for
pharmacologic cardioversion. The evidence for flecainide for
acute (rapid) conversion to sinus rhythm is based on several
RCTs of modest size and one meta-analysis [138–142]. The
evidence for amiodarone for acute (delayed) conversion to
sinusrhythm involves more RCTs including one meta-analysis
[142–145]. Compared with amiodarone, flecainide results in
earlierandmoreeffectiveconversiontosinusrhythm[138,142].
The evidence for sotalol in acute conversion to sinus
rhythm is limited. Some data suggest similar but low efficacy
of oral sotalol compared with amiodarone (27% at 28 days);
other data suggest that sotalol has lower efficacy than flecai-
nide and amiodarone [146–149]. In view of this uncertainty,
these guidelines do not recommend the use of sotalol for the
acute reversion to sinus rhythm.
Electrical cardioversion may be required to facilitate res-
toration of sinus rhythm in stable patients if pharmacother-
apy fails or is not tolerated. Pre-treatment with AADs can
improve the efficacy of electrical cardioversion. The choice of
AAD is discussed below (Section 5.3.2).
Benefits and harms: There is some variation in reported
efficacy of AADs for cardioversion. Success rates for flecai-
nide range from 55% to 85%, and for amiodarone from 35% to
90% [150]. One meta-analysis comparing Class IC agents
(including flecainide) to amiodarone suggested that the for-
mer were more than twice as likely to revert patients within
the first 3–5 hours (50% vs 22%) [142].
Practice advice: Electrical cardioversion may be less desir-
able in the older patient due to the need for general anaesthetic,
and the increased risks of cognitive change and delirium in this
population. Outpatient oral flecainide for acute reversion (the
‘pill-in-pocket’ approach) should be used in conjunction with
an AV nodal block agent (taken at least 30 minutes prior) to
avoid 1:1 conduction of atrial flutter.
In patients with an AF duration of more than 48 hours or of
unknown duration, acute rhythm control should generally
not be attempted unless LA thrombus is excluded with TOE.
5.3.2. Long-term Rhythm Control
Recommendation: Flecainide can be considered in the
maintenance of sinus rhythm in patients without left ven-
tricular systolic dysfunction, moderate left ventricular
hypertrophy, or coronary artery disease.
(GRADE quality of evidence: High; GRADE strength of rec-
ommendation: Strong.)
Recommendation: AV nodal blocking medication is rec-
ommended for patients treated with flecainide.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Amiodarone can be considered for
maintenance of sinus rhythm as a second-line agent or
as a first-line agent in patients with left ventricular systolic
dysfunction, moderate left ventricular hypertrophy, or cor-
onary artery disease.
(GRADE quality of evidence: High; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Sotalol may be considered for main-
tenance of sinus rhythm but requires close monitoring of
QT interval.
(GRADE quality of evidence: High; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Beta adrenoceptor antagonists may be
considered for the maintenance of sinus rhythm.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Weak.)
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Rationale: The decision to aim for rhythm (instead of rate)
control requires discussion between the patient and the treat-
ing physician. Factors favouring rhythm over rate control
include patients who are younger, more physically active
and highly symptomatic; those with paroxysmal or early
persistent AF; and those with LV dysfunction; no severe
LA enlargement; and those in whom adequate control of
the ventricular rate is difficult to achieve (see Table 2) [150].
On average, AAD therapy reduces the risk of AF recur-
rence by 50% compared with placebo. There is currently no
published randomised study suggesting that rhythm control
is associated with decreased stroke risk and mortality. The
results of the Catheter Ablation vs Anti-arrhythmic Drug
Therapy for Atrial Fibrillation (CABANA) trial addressing
this question were recently presented and are discussed
below (see Section 5.3.3) A second study in this area, Early
Treatment of Atrial Fibrillation for Stroke Prevention Trial,
Atrial Fibrillation Network (EAST-AFNET-4) is awaited.
The choice of AAD therapy depends on the patient’s
comorbidities (e.g., presence of structural heart disease, cor-
onary artery disease, or renal dysfunction) and preferences,
and requires a discussion of the risks and benefits with the
patient (see Figure 5).
Several RCTs [149,151,152] and meta-analyses support the
superior efficacy of amiodarone over other AADs or placebo
in maintenance of sinus rhythm [153,154]. However, amio-
darone is associated with potential long-term toxicities, and
therefore should not be a first-line treatment choice in
patients suitable for other drug(s).
A limited number of prospective observational studies,
RCTs, and meta-analyses support the efficacy of flecainide
in maintenance of sinus rhythm [153,155,156]. Flecainide
should be used in conjunction with an AV nodal block agent
to avoid 1:1 conduction of atrial flutter, and should not be
used in patients with LV systolic dysfunction, moderate LV
hypertrophy, or coronary artery disease.
A number of RCTs and meta-analyses support the modest
efficacy of sotalol in maintenance of sinus rhythm
[149,151,157,158]. It is less effective than alternatives and
torsades de pointes occurs in about 2% of patients [159]. A
recent Cochrane review [153] suggests increased mortality
with sotalol. Close monitoring of the QT interval is therefore
required, particularly in older people, women and those with
impaired renal function [160].
Two small placebo-controlled studies with persistent AF
have found a lower risk of recurrence after cardioversion
with sustained release metoprolol [161,162] and one study
suggested comparable efficacy between beta blockers (meto-
prolol and atenolol) and sotalol [163]. However, beta blockers
are generally regarded as less effective than AAD in the
maintenance of sinus rhythm [1,2,153].
Class Ia AADs (quinidine and disopyramide) appear more
effective than placebo in maintenance of sinus rhythm; how-
ever, meta-analyses of RCTs similarly suggest increased
mortality associated with these drugs [153,164], and hence
they are not recommended for the maintenance of sinus
rhythm. The only exceptions to this are for disopyramide
in specific situations; it may have a role in some cases of
vagally mediated AF and in patients with hypertrophic
obstructive cardiomyopathy [165,166].
Benefits and harms: In a comprehensive Cochrane review,
pooled recurrence rates of AF at 12 months were 69%–84% in
controls not receiving antiarrhythmic treatment but were
reduced to 43%–67% in patients treated with AADs. The
corresponding average numbers needed to treat for 1 year
to avoid one recurrence of AF were three with amiodarone,
four with flecainide, eight with sotalol, and nine with meto-
prolol [153]. Proarrhythmia was observed less frequently.
The number needed to treat, to harm with one proarrhythmic
event, was 38 with both flecainide and sotalol. Amiodarone
and metoprolol were not associated with proarrhythmia. The
number needed to treat with sotalol to cause one excess death
was 169, but 95% CIs were wide (60–2067) [153].
Practice advice: Adjunctive lifestyle modification and
strict cardiovascular risk factor control should not be over-
looked in rhythm control management of AF (see Section
4.5.4) [98,100].
5.3.3. Percutaneous Catheter Atrial Fibrillation Ablation
Recommendation: Catheter ablation should be considered
for symptomatic paroxysmal or persistent AF refractory or
intolerant to at least one Class I or III antiarrhythmic medi-
cation.
(GRADE quality of evidence: High; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Catheter ablation can be considered
for symptomatic paroxysmal or persistent AF before initia-
tion of antiarrhythmic therapy.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Catheter ablation can be considered
for symptomatic paroxysmal or persistent AF in selected
patients with heart failure with reduced ejection fraction.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: Theserecommendationsandcommentaryarecom-
plementary to and update those provided in the NHFA consen-
sus statement on catheter ablation as a therapy for AF [167].
AF ablation is an effective procedure for appropriately
selected patients with symptomatic AF. It is applicable to
patients who have failed or are intolerant to AADs, or for some
patients who decline AAD treatment (see Figure 5). Patients
frequently report a dramatic improvement in quality of life
with AF ablation. Multiple RCTs have demonstrated higher
ratesofsinusrhythm maintenancecompared with AADs[168].
Recent evidence demonstrates that the procedure may
have a mortality benefit in patients with heart failure
[133]. Ongoing studies are evaluating the potential for stroke
risk reduction and reduction in mortality in patients with AF.
The results of one of these trials, Catheter Ablation vs Anti-
arrhythmic Drug Therapy for Atrial Fibrillation (CABANA),
was recently presented [169]. In this study 2204 AF patients
tolerant of at least two AADs and with one risk factor for
stroke were randomised to catheter ablation or drug therapy.
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The primary outcome of death, disabling stroke, serious
bleeding, or cardiac arrest at 5 years was not significantly
different between ablation versus drug therapy. There was a
significant reduction in AF burden and improvement in
quality of life with ablation. Publication of CABANA is
awaited. In the discussion with the patient it is important
to emphasise that 20%–30% of ablation patients will require a
second procedure within the first 12 months. Published
major complication rates range from 1% to 7%, with rates
being lower for experienced centres and operators.
Certain patient characteristics can be used to define
patients in whom a lower success rate or a higher complica-
tion rate is likely. These characteristics include the presence
of concomitant heart disease, obesity, sleep apnoea, LA size,
Figure 5 Long term rhythm control strategies.
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patient age and frailty, as well as the duration of time the
patient has been in continuous AF. Although these factors do
not constitute contraindications to the procedure, each
should be considered when discussing the risks and benefits
of AF ablation with a patient.
In patients at increased risk of stroke, anticoagulation
should be continued indefinitely, even following a successful
procedure (see Section 6.3.4.5).
AF ablation may be considered in selected asymptomatic
patients after a clear discussion of risks and benefits.
Benefits and harms: A meta-analysis of eight RCTs (844
patients), with follow-up ranging from 6 to 12 months,
reported freedom from recurrent AF rates of 76.8% in
patients in the ablation group and 23.4% in patients receiving
an AAD. The rate of major complications in the ablation
group was 6.2% [170].
Practice advice: International guidelines recommend that
this procedure be performed only in centres with onsite
cardiac surgery. Furthermore, there is observational evi-
dence that outcomes are better when experienced operators
are performing the procedure in high-volume centres. Oper-
ators with fewer than 25 procedures annually and hospital
volumes of fewer than 50 procedures annually have been
significantly associated with adverse outcomes [171]. Pub-
lished complication rates from experienced Australian insti-
tutions have been about 1% [172].
Early in the course of their AF journey, some patients
might have only infrequent episodes for many years, or could
have AF that is responsive to well-tolerated AAD therapy. In
patients with recently diagnosed AF, ablation can be deferred
until the natural history in that individual patient is declared.
5.3.4. Surgical Management of Atrial Fibrillation in the
Context of Concomitant Cardiac Surgery
Recommendation: Surgical ablation of AF to restore sinus
rhythm in the context of concomitant cardiac surgery may
be considered for patients with symptomatic paroxysmal,
persistent, or long-standing persistent AF.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: The presence of AF in patients undergoing aortic
valve replacement (AVR) or coronary artery bypass grafting
(CABG) (i.e. non-atriotomy cardiac procedures) or mitral
valve surgery (i.e. atriotomy cardiac procedure) has been
shown in multiple studies to be associated with increased
rates of early and late morbidity and mortality [173,174].
Most of the studies comparing CABG with concomitant
surgical ablation of AF with CABG alone showed benefit in
terms of reduction in AF recurrence, and no significant dif-
ference in morbidity or mortality [174–177]. One important
consideration relating to the harms of concomitant surgical
ablation and CABG is the increased cardiopulmonary bypass
time that is required for this concomitant procedure [178].
The problem in interpreting the data from the literature
surrounding this topic is that most studies group non-atriot-
omy cardiac procedures (i.e. CABG and AVR), making it
difficult to apply the results to a selected procedure group.
The literature also reports different ablative sources (e.g.,
radiofrequency and cryoablation) and different surgical tech-
niques (e.g., epicardial versus endocardial ablation). Some
studies have also noted that duration of AF and LA size are
important predictors of ablation failure [177,179].
Benefits and harms: Surgical ablation for AF in the context
of concomitant CABG has been shown to produce AF-free
rates of greater than 85% at 18-month follow-up, compared
with AF-free rates of below 50% in the CABG-only groups at
the same endpoint [174,176,177,180–182].
Resources and other considerations: Surgical management
of AF is only available for patients at centres with a specialist
cardiothoracic service.
Practice advice: Patients should be considered on an indi-
vidual basis in a multidisciplinary team meeting that includes
both the treating cardiologist and cardiothoracic surgeon and
aims to determine the best management plan for each patient.
Surgical expertise and training in these surgical ablation pro-
cedures are of key importance to optimise patient outcomes.
Surgeons should ensure that they undergo recognised surgical
ablation courses to understand the fundamentals of the pro-
cedure, and that they are adequately proctored at the com-
mencement of their program. In patients at increased risk of
stroke, anticoagulation should be continued indefinitely, even
following a successful procedure (see Section 6).
5.3.5. Stand-alone Surgical and Hybrid Management of
Atrial Fibrillation
Recommendation: Stand-alone surgical or hybrid ablation
of AF can be considered for patients with symptomatic
paroxysmal, persistent or long-standing persistent AF that
is refractory, or intolerant to at least one Class I or III
antiarrhythmic medication, or where there has been failed
percutaneous ablation, or where the likelihood of success-
ful percutaneous ablation is considered low.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Weak.)
Rationale: The surgical management of AF was first reported
in the literature by Cox and his colleagues, who described their
‘Cox-Maze procedure’, which showed excellent results in ter-
minating AF [183]. Since then, several modifications to the
original procedure have been made; however, the procedure
is time consuming, technically challenging, and invasive, and
requires cardiopulmonary bypass. Therefore, research has
focused on newer procedures that are minimally invasive
and use thoracoscopic guidance and an energy source (either
radiofrequency orcryoablation) tocreateepicardial lesions, the
aim being to provide evidence for a safer and less invasive
surgical procedure for the stand-alone management of AF
[184,185]. A recent focus of research has been a hybrid proce-
dure that combines both a surgical epicardial ablation proce-
dure and a catheter endocardial procedure (either staged or
simultaneously) to achieve better outcomes for patients.
The body of literature surrounding the stand-alone surgi-
cal management of AF mostly comprises observational stud-
ies with varied cohort sizes, and the results must be
interpreted cautiously.
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Benefits and harms: A review of the above literature
revealed that the surgical management of AF produces
AF-free rates of 82% with AADs and 65% without AADs
at mean follow-up of 28.6 months (16.6). Estimates of the
complication rates associated with these procedures revealed
the risk of death as 0.5%, conversion to sternotomy 1.1%,
bleeding 2.1%, stroke or TIA 0.8%, permanent pacemaker
insertion 1.6% and phrenic nerve injury 1.1%.
Resources and other considerations: Surgical management
of AF is only available for patients at centres with a cardio-
thoracic service; therefore, it might not be a feasible treatment
option for patients living in rural or remote areas.
Practice advice: Patients should be considered on an indi-
vidual basis in a multidisciplinary team meeting that
includes both the treating electrophysiologist and cardiotho-
racic surgeon, with the aim of determining the best manage-
ment plan for each patient. Surgical expertise and training in
these newer minimally invasive epicardial procedures are of
key importance to optimise patient outcomes.
5.4. Arrhythmia Management in Special
Situations
5.4.1. Arrhythmia Management—Atrial Flutter
RCT data comparing rate and rhythm control strategies in
individuals with atrial flutter are sparse. Within the subgroup
of patients with atrial flutter that were included in the Rate
Control Versus Electrical Cardioversion for Persistent Atrial
Fibrillation (RACE) trial, there was no significant difference in
outcomes between the rate-control and rhythm-control groups
with respect to the primary endpoint [120]. Options for rhythm
control in atrial flutter include electrical cardioversion, cavo-
tricuspid isthmus (CTI) ablation (for typical atrial flutter) or
AAD therapy. Observational studies have shown that electri-
cal cardioversion can facilitate acute rhythm control in more
than 90% of cases [186–188]. For sustained rhythm control,
small RCTs have found CTI ablation to be significantly better
than AADs for preventing atrial flutter recurrence. Atrial flut-
ter recurrence rates of 6.4%–8.7% were reported in patients
treated with CTI ablation compared with 50%–52.9% in
patients receiving AADs [189,190]. A meta-analysis of studies
that performed CTI ablation with large-tip or irrigated cathe-
ters and employed bidirectional isthmus block as the proce-
dural endpoint reported a mean atrial flutter recurrence rate of
6.7% and a complication rate of 2.7% (most of which were
vascular complications) [191]. Despite the efficacy of CTI abla-
tion in curing atrial flutter, 51.3% of patients with pre-existing
AF will experience AF recurrence post-CTI ablation, and 26.2%
of patients with no previous history of AF will develop new AF
if followed up for at least 2 years [192]. Unfortunately, no large
studies have compared CTI ablation to AAD and incorporated
atrial arrhythmia recurrence as an endpoint.
5.4.2. Arrhythmia Management in Hypertrophic
Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common
inherited cardiovascular condition; it has an estimated prev-
alence of 0.2%–0.5% [193]. AF in turn is the most common
sustained arrhythmia in HCM patients, with a prevalence of
nearly one in four and an annual incidence of 3% [194]. The
development of AF in HCM patients is associated with an
increased risk of stroke, impaired quality of life, increased
hospitalisation, and higher mortality [195–199].
Data regarding rate versus rhythm control in AF patients
with HCM are limited. However, the symptomatic and prog-
nostic impact of AF on HCM patients—particularly in the
presence of rapid ventricular rates or left ventricular outflow
tract (LVOT) obstruction—makes the restoration of sinus
rhythm the recommended strategy [195,200]. Haemodynami-
cally unstable patients or those with severe symptoms require
urgent cardioversion. Beta blockers and non-dihydropyridine
calcium channel blockers are reasonable agents to use for rate
control, given their established safety and efficacy profiles, as
well as the desired negative inotropic effect, which can ame-
liorate the haemodynamic consequences of AF [201,202]. In
contrast, digoxin is contraindicated when there is LVOT
obstruction [200]. Disopyramide, a Class Ia AAD, is often used
to treat LVOT obstruction in combination with a rate-limiting
medication (because it can increase AV nodal conduction), but
its use to treat AF is not established [165,200].
Amiodarone (a Class III AAD) has long been used for the
treatment of AF in HCM patients [203–206], but its toxicity
limits its long-term use, and it has similar efficacy to other
AADs [198]. Sotalol has been shown to be successful in
suppressing atrial arrhythmias [207–209], but careful moni-
toring is required because of its proarrhythmic, QT-prolong-
ing effect [200]. A retrospective study of 4248 HCM patients
showed that the protective effect of beta blockers, non-dihy-
dropyridine calcium channel blockers, and disopyramide in
preventing AF recurrence is limited to two to three years
[198]. Class IC antiarrhythmics such as flecainide should be
avoided due to their proarrhythmic effects [200].
Multiple small studies have shown catheter ablation for AF
to be a reasonable and safe option to maintain sinus rhythm
and improve symptoms in HCM patients [210]. A systematic
review of 14 observational studies reported freedom from
atrial arrhythmia following catheter ablation in 51.8% of
patients, with a median follow-up of 1.8 years after a median
of 1.4 procedures [211] (see Section 5.3.3).
5.4.3. Arrhythmia Management for Post-operative Atrial
Fibrillation
Postoperative AF is well-documented, with an incidence of
8%–50%, depending on the type and site of the surgery [212–
215].AFisresponsible for increasingthepostoperativehospital
length of stay and is an independent predictor of mortality
[3,216].Althoughseveralobservationalstudieshavesuggested
a survival benefit following restoration of the sinus rhythm
following cardiovascular surgery [213,215,217], the most
recent RCT that studied the effectiveness and safety of rate
control versus rhythm control after cardiothoracic surgery
showed equal duration of hospital stay and complications
[218]. Postoperative AF management remains controversial,
and evidence to support rhythm control versus rate control in
this population of patients is lacking.
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5.4.4. Arrhythmia Management in Grown-up Patients
with Congenital Heart Disease
The occurrence of atrial arrhythmia, including AF, in grown-
up patients with congenital heart disease (GUCH) increases
with age, complexity of congenital heart disease (CHD), and
the timing and number of surgical interventions undertaken.
Overall, atrial arrhythmias are usually seen late after surgical
repair of CHD, occurring in 25%–40% of GUCH patients. The
atrial arrhythmias are poorly tolerated and are associated
with heart failure, thromboembolism, syncope, and sudden
death [219–222].
Class IC and III agents are effective in treating atrial arrhyth-
mias.Amiodarone is moreeffective and is recommendedin the
presence of ventricular dysfunction [222]. However, long-term
treatment carries a high risk of side effects in this relatively
young population. Radiofrequency ablation should be consid-
ered for symptomatic GUCH patients with atrial arrhythmias
or drug-refractory AF [223–225]. Atrial arrhythmias may also
be the first manifestation of failing or obstructed atriopulmo-
nary anastomosis circuits. Operative conversion to total cav-
opulmonary artery connection with arrhythmia surgery in
selected patients improves heart failure and reduces recurrent
arrhythmias [226].
5.4.5. Arrhythmia Management in Athletes
An increasing amount of data shows an excess of AF among
athletes, particularly those engaged in endurance sports.
Recent estimates from large-cohort studies show a 20%–
30% increased risk among athletes [227], although previous
estimates from case–control studies had suggested a five-fold
increase in risk. The mechanisms contributing to AF in ath-
letes are unclear, although they are probably due to an
increase in parasympathetic tone coupled with the develop-
ment of an arrhythmogenic substrate [228].
Although few studies have assessed treatment strategies
among athletes, rhythm control is often the preferred approach
because it has less impact on exercise performance, and
because rate control can be difficult due to the baseline level
of bradycardia observed in this population. Several small
studies have compared catheter ablation outcomes between
athletes and non-athletes, showing comparable freedom from
AF [229,230]. Rate control may be appropriate, although its
impact on exercise tolerance should be considered.
6. Stroke Prevention
6.1. Prediction of Stroke Risk
Recommendation: The CHA2DS2-VA score—the sexless
CHA2DS2-VASc score—is recommended for predicting
stroke risk in AF.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: The CHA2DS2-VA score should be re-
evaluated yearly in low-risk patients who are not antico-
agulated.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Rationale: Development of the CHADS2 score using simple
clinical markers allowed some prediction for risk of stroke
among patients with non-valvular AF, although the predic-
tive capacity was modest. Other scores have produced minor
improvements, especially in the low-risk group, and com-
parisons between different scores (e.g., CHA2DS2-VASc,
ATRIA, and ORBIT) do not show major differences in pre-
dicting high risk of stroke. A systematic review has provided
the strength of the stroke risk factors used in the CHA2DS2-
VASc score [231].
Of the available scores the CHA2DS2-VASc score is simple to
use, widely known, and accepted in clinical practice. The
female sex category component of the score (Sc) adds the most
predictive value in the presence of multiple additional risk
factors. Female sex alone or in the presence of one additional
risk factor does not confer sufficient or consistent increased risk
[232–234]. Most guidelines have adopted the cumbersome
practice of selecting different CHA2DS2-VASc thresholds for
males and females when recommending anticoagulation. To
avoid this practice, we recommend a sexless CHA2DS2-VASc
score (i.e. removing female sex), abbreviated as CHA2DS2-VA
score in these guidelines, and we provide one consistent rec-
ommendation for both sexes (see Table 3).
Resources and other considerations: The addition of bio-
markers (e.g., troponin, B-type natriuretic peptide [BNP] [235],
transthoracic and transoesophageal echo measurements) to
existing scores improves overall predictive capacity. However,
these algorithmshave notbeenevaluatedinsufficient numbers
of low-risk patients on no therapy to demonstrate their value in
reliably differentiating those with truly low risk who do not
require anticoagulation from those with low to intermediate
risk who do require anticoagulation. Moreover, biomarker use
adds measurement and biological variability, and additional
steps, which increase complexity relative to the simple bedside
clinical score risk estimation. Some ongoing studies will
address whether biomarkers will allow adequate risk discrim-
ination in patients at low to intermediate predicted risk to
permit a greater number of patients to safely be managed
without lifelong anticoagulants.
Practice advice: The definitions of the letters in the acro-
nym CHA2DS2-VA are shown in Table 3. Stroke risk factors
may change over time due to ageing or development of new
comorbidities. Hence, annual review of low-risk patients is
recommended to ensure that risk is adequately characterised
to guide OAC therapy.
6.2. Prediction and Minimisation of
Bleeding Risk
Recommendation: Reversible bleeding factors should be
identified and corrected in AF patients for whom antico-
agulation is indicated.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
6.2.1. Prediction of Bleeding Risk
The risk of bleeding with warfarin is 1.3% per year in patients
with an INR of 2.0–3.0 [236], but estimates vary widely,
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depending on the population studied and the quality of INR
control for warfarin.
NOACs have either a comparable or a slightly reduced
major bleeding risk relative to warfarin, with the difference
being more pronounced in centres with lower time in thera-
peutic range for warfarin, a greater incidence of gastrointes-
tinal (GI) bleeding and a significantly reduced risk of
intracranial haemorrhage [237]. Bleeding risk can be esti-
mated by a variety of clinical scores—for example, HEMOR-
R2HAGES [238], HAS-BLED [239], ATRIA [240], ORBIT
[241], and GARFIELD [242]—and by ABC (age, biomarkers,
clinical history) bleeding risk score [243] incorporating bio-
markers. C statistics for predicting major bleeds are modest
at best (0.6), and adding biomarkers provides only minimal
improvement. Higher CHADS2 and CHA2DS2-VASc scores
also predict major bleeding, which indicates that patients at
high risk of stroke are also at higher risk of major bleeding,
but the specialised bleeding risk scores are better predictors
[244]. The net clinical benefit almost always favours stroke
prevention over major bleeding, so bleeding risk scores
should not be used to avoid anticoagulation in patients with
AF. Higher scores might be used to alert the clinician to a
greater need to attend to any modifiable bleeding risk factors.
6.2.2. Minimisation of Bleeding Risk
Treating reversible bleeding risk factors such as hyperten-
sion, falls and peptic ulceration should be prioritised to
minimise the bleeding rate in patients on anticoagulants
(see Table 4). The risk associated with recurrent falls may
be reduced by falls prevention programs. In people with
recurrent falls despite efforts to decrease risk of falling, a
more detailed discussion may need to be had on the risks
associated with continuing anticoagulation versus the risks
associated with stopping anticoagulation. The difficulty for
clinicians and patients is that there is no high-quality evi-
dence to help guide this discussion.
In secondary prevention after cerebrovascular events, the
risk of intracranial haemorrhage (ICH) can be reduced from
2% to 1% through reduction in blood pressure (BP) [245].
Reintroduction of anticoagulants after both spontaneous and
traumatic ICH on warfarin reduces ischaemic stroke or sys-
temic embolus and mortality [246]. Patients who have had
unprovoked (spontaneous) ICH should have a specialist
assessment of their bleeding risk on an OAC.
The presence of congophilic angiopathy, also known as
cerebral amyloid angiopathy (CAA) and cerebral micro-
bleeds on magnetic resonance imaging (MRI) are markers
for heightened ICH rates on anticoagulants. Symptomatic
ICH, related to CAA, is a relative contraindication to anti-
coagulation, although this may be considered in individual
patients 4–6 weeks following lobar haemorrhage.
Asymptomatic CAA on MRI sequences, without ICH, is
highly prevalent, being 16% in older patients [247], and is not
a contraindication to anticoagulation.
Most significant bleeds before anticoagulation and after
anticoagulation occur from the GI tract (GIT). Causes of prior
upper GIT bleeding in cardiovascular prevention, such as
peptic ulceration, are usually preventable [248] and are not a
contraindication. Dabigatran 150 mg and rivaroxaban 20 mg
were associated with increased GI bleeding relative to war-
farin in RCTs. Other agents or doses should be preferentially
used in patients with prior GI bleeding. Untreatable or diffi-
cult to prevent causes of lower GIT bleeding (e.g., recurrent
bleeding from angiodysplasia) may be a contraindication to
anticoagulation.
Practice advice: Major bleeding can be reduced through
high-quality INR control on warfarin [249], and appropriate
selection of NOAC dosage according to age and renal func-
tion [248,250].
Recurrent falls are associated with increased mortality in
AF patients but not increased ICH, although these data come
from a Markov modelling analysis that has been criticised for
Table 3 Definitions and points in the CHA2DS2-VA score.
Score Points Definition
C 1 Congestive heart failure—recent signs, symptoms or admission for decompensated heart failure; this includes
both HFrEF and HFpEF, or moderately to severely reduced systolic left ventricular function, whether or not
there is a history of heart failure
H 1 History of Hypertension, whether or not BP is currently elevated
A2 2 Age 75 years
D 1 Diabetes
S2 2 History of prior Stroke or TIA or systemic thromboembolism
V 1 Vascular disease, defined as prior myocardial infarction or peripheral arterial disease or complex aortic atheroma
or plaque on imaging (if performed)
A 1 Age 65–74 years
AF, atrial fibrillation; BP, blood pressure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; TIA, transient
ischaemic attack.
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assuming no pre-existing comorbidities in the patient popu-
lation. Under certain circumstances (e.g., frail people and
older people, see Section 6.3.4.2), a high bleeding score
should prompt a discussion between physician and patient
in which the facts and physician’s opinion are presented,
allowing the patient or carer to make an informed decision.
In Australia, high ICH rates have been observed in those
born in Oceania (other than Australia) and in northeast and
southeast Asia [251]. In Aboriginal people, the risk of ICH has
been reported as markedly increased (up to six-fold) (see
Section 6.3.4.3) [252].
6.3. Stroke Prevention with
Anticoagulation
Recommendation: Oral anticoagulation therapy to prevent
stroke and systemic embolism is recommended in patients
with N-VAF whose CHA2DS2-VA score is 2 or more, unless
there are contraindications to anticoagulation.
(GRADE quality of evidence: High; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Oral anticoagulation therapy to
prevent stroke and systemic embolism should be con-
sidered in patients with N-VAF whose CHA2DS2-VA
score is 1.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Oral anticoagulation therapy to
prevent thromboembolism and systemic embolism is not
recommended in patients with N-VAF whose CHA2DS2-
VA score is 0.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Weak.)
Table 4 Bleeding risk factors.
Modifiable bleeding risk factors Comment
Hypertension (SBP >160) Blood pressure control reduces the potential risk of bleeding
Labile INR (TTR <60%) Consider changing to a NOAC
Concomitant medications including
antiplatelet agents and NSAIDs
Minimise duration of double or triple therapy in patients with coronary
disease and AF
Excess alcohol (>8 drinks per week)
Potentially modifiable bleeding risk factors Correct these factors where possible
Anaemia
Impaired renal function Monitor, especially in situations when renal function may be affected
Impaired liver function
Frailty and falls Walking aids, footwear, aged care home review
Non-modifiable bleeding risk factors
Advanced age Stroke risk outweighs bleeding risk
History of major bleeding
Previous stroke Risk of recurrent stroke outweighs risk of bleeding
Dialysis-dependent kidney disease The role of anticoagulation (warfarin only indicated) in this population is
controversial
Cirrhotic liver disease Contraindication to NOACs (these patients are excluded from trials); consider
advice from hepatologist
Malignancy Individualise decisions about anticoagulation based on risk and benefit
Genetic or racial variation Subgroup analyses from the NOAC versus warfarin RCTs suggest that,
when warfarin is used, Asian patients are at higher risk of major bleeding
and ICH than non-Asians; standard-dose NOACs appear to be as effective in
Asians as non-Asians [419]
ICH risk is high in Aboriginal and Torres Strait Islander patients on
anticoagulation [252]
Pay careful attention to blood pressure control in these populations
AF: atrial fibrillation, ICH: intracranial haemorrhage, INR: international normalised ratio, NOAC: non-vitamin K oral anticoagulant, NSAID: nonsteroidal
antiinflammatory drug, RCT: randomised controlled trial, SBP: systolic blood pressure, TTR: time in therapeutic range.
Kirchhof P, et al. 2016. Eur Heart J 2016; 37 (38): 2893–2962. By permission of OUP on behalf of the ESC. This table is not included under the Creative Commons license of this
publication. © ESC 2016. All rights reserved. For permissions email journals.permissions@oup.com [1].
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Recommendation: In asymptomatic patients with atrial
lead pacemakers, anticoagulation should be considered in
device-detected and EGM-confirmed AF of 24 hours or
more in patients with a CHA2DS2-VA score of 2 or more.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: When oral anticoagulation is initi-
ated in a patient with N-VAF, an NOAC—apixaban, dabi-
gatran, or rivaroxaban—is recommended in preference to
warfarin.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Warfarin is recommended and
NOACs should not be used in patients with valvular AF
(mechanical heart valves or moderate to severe mitral ste-
nosis).
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Antiplatelet therapy is not recom-
mended for stroke prevention in N-VAF patients, regard-
less of stroke risk.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: The guiding principle for use of the CHA2DS2-
VA score is to define truly low-risk patients for whom stroke
risk is too low to justify the risk of major bleeding from
anticoagulant therapy. Thus, the score is not used to provide
an arbitrary allocation to low, medium, or high stroke risk,
nor to concentrate on high risk, but rather to define low risk;
that is, a CHA2DS2-VA score of 0. For a CHA2DS2-VA score of
2 or more, the benefits of reduced stroke and reduced mor-
tality from anticoagulation certainly outweigh the risk of
major haemorrhage, and an OAC is recommended. At a
CHA2DS2-VA score of 1, the risk–benefit equation is more
balanced, so other factors require greater consideration in the
decision on anticoagulation (see Figure 6).
Asymptomatic patients with AF detected on opportunistic
screening are regarded as having a comparable risk to symp-
tomatic patients; thus, recommendations for anticoagulation
apply (see Section 4.4.2 Figure 1).
Patients with atrial flutter have a slightly lower stroke risk
than patients with atrial fibrillation, but the risk still exists
[253]. Furthermore, many of these patients have episodes of
atrial fibrillation so the same recommendations for antico-
agulation apply.
The stroke risk for patients with implantable devices and
incidentally detected AF appears to be lower than in the
general AF population, and there are less data to guide
the threshold AF burden upon which to recommend anti-
coagulation (see Section 4.4.2 Figure 1). However, because of
the high rate of progression to clinical episodes and the
greater burden, patients with a CHA2DS2-VA score of 2
should have close follow-up with consideration of OAC
when an episode lasts for more than 24 hours. There are
insufficient data to provide recommendations for patients
with lower burdens of implanted-device-detected AF,
regardless of CHA2DS2-VA score.
Anticoagulation with warfarin reduces the risk of embolic
stroke by 70% and of mortality by 29% when used in patients
with N-VAF. However, warfarin is difficult to use in clinical
practice because of multiple food and drug interactions, and
the need for frequent monitoring to keep the anticoagulation
within the therapeutic range [2,254]. As with all forms of
antithrombotic or anticoagulant therapy, bleeding is
increased with warfarin, but ICH is greatly increased com-
pared with other agents [255–257].
The evidence for stroke prevention with aspirin is weak
[255,258], and it is not as benign as many think, with data
suggesting that bleeding rates were similar to apixaban in
patients with N-VAF who were deemed ineligible for anti-
coagulation with warfarin [259]. Aspirin together with clo-
pidogrel reduced stroke by 28% when compared with aspirin
alone, but at the expense of a 57% increase in major bleeding.
The combination antiplatelet therapy was 44% less effective
than warfarin in stroke prevention, with comparable inci-
dence of major bleeding [260].
There are strong data to show that the NOACs (dabigatran,
rivaroxaban, and apixaban, also known as ‘direct-acting oral
anticoagulants’ or ‘DOACs’; see Table 5) are as good as or
better than warfarin in reducing stroke and systemic embo-
lism, and that bleeding rates are less or similar to warfarin,
depending on the agent chosen and the dose used. ICH is
significantly reduced with all agents compared with warfa-
rin, independent of the dose used, and pooled data suggest
there is a mortality benefit over warfarin. NOACs have
minimal drug and food interactions, and do not need hae-
matological monitoring, so are much easier for the patient
and physician to use [237,261–263].
These data form the basis for the strong recommendation
that NOACs are preferred over warfarin for stroke preven-
tion in N-VAF if the patient is eligible [15].
Benefits and harms: The NOACs have overall better or
similar efficacy and safety when used in patients with N-VAF
for stroke prevention compared with warfarin, but the abso-
lute risk reductions are relatively small, so the number
needed to treat to prevent stroke, and to reduce ICH and
mortality is in the hundreds relative to warfarin [237].
Resources and other considerations: The NOACs are con-
siderably more expensive than warfarin, but cost–benefit
analyses, admittedly in countries where medical costs are
higher [264,265], have shown that NOACs are cost effective
compared with warfarin using conventional measures. There
are no Australian data on this, but the Pharmaceutical Bene-
fits Advisory Committee has funded these drugs, and is
satisfied that they provide good value for money in an
Australian context.
Australia is a large country, and medical resources and the
ability to monitor INRs are often scarce in remote communi-
ties. In such communities, NOACs have the capacity to
greatly improve the health of patients with N-VAF and risk
factors for stroke, because monitoring is not required and
patients who were previously considered poor candidates
for anticoagulation with warfarin due to these constraints can
be treated with proven alternative therapy.
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Practice advice: There are some clinically significant dif-
ferences between the NOACs that need to be considered
when prescribing these drugs (see Table 5).
Full anticoagulation is achieved within 1–2 hours of dosing
for all agents due to their rapid onset of action [262,263,266].
Similarly, they also have a rapid offset of action compared
with warfarin, so that within 24 hours of taking the last dose,
minimal anticoagulant effect remains. Missed doses are
problematic due to the rapid offset of action, which could
potentially increase risk of stroke due to periods of non-
anticoagulation. This is less of an issue with warfarin, which
has a much longer half-life.
Figure 6 Stroke prevention in atrial fibrillation.
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The NOACs are all renally excreted, with dabigatran being
most dependent on renal excretion, and rivaroxaban and
apixaban less so. Thus, in the presence of renal dysfunction,
a longer treatment discontinuation period is required with
dabigatran than with the other agents to allow coagulation
status to return to normal. Dabigatran and rivaroxaban
should be taken with meals to reduce the risk of dyspepsia
and improve absorption, respectively.
The relationship between the INR and activated partial
thromboplastin time (APTT) and drug levels is nonlinear;
thus, it is not helpful in determining the extent of antico-
agulation. These tests, however, can be used to assess medi-
cation adherence, because levels are usually elevated when
the patient has taken the drug. Similarly, these tests can be
useful in patients requiring urgent surgery or treatment for
bleeding, because normal levels of these parameters would
suggest that very little active drug is present.
In patients with stable INR control on warfarin, it is rea-
sonable to consider changing to a NOAC on the basis of the
consistent decrease in ICH with all doses of the NOACs
compared with warfarin. Patient wishes need to be consid-
ered in this context (see Section 7.2); for example, the absence
of the need for haematological monitoring and the ability to
have a more liberal diet may influence some patients,
whereas others may prefer the reassurance offered by a
therapeutic INR taken on a regular basis.
6.3.1. Optimising Anticoagulation
For warfarin, optimal therapeutic outcomes are achieved
within a narrow therapeutic index; therefore, treatment
is carefully dosed according to a specified target INR
range. To facilitate these dosage adjustments, regular INR
measurement is needed for the duration of the warfarin
therapy. There are various approaches to achieving this,
including:
 general practitioner (GP) led management;
 anticoagulation clinic;
 pathology service-led care (with validated computerised
dosing algorithms);
 point-of-care testing (including patient self-management).
Although point-of-care INR testing is becoming more com-
mon in Australian practice, for most patients the process of
INR measurement and dosage adjustment is still undertaken
collaboratively by the GP and local pathology service. Typi-
cally, the patient’s GP (prescriber) refers the patient to a local
pathology service for blood tests. INR test results are
reported back to the GP (typically electronically) for their
review; INR results that are out of range are communicated
back to the patient by either the GP or the pathology service,
alerting the patient to the need for a dosage adjustment (as
prescribed by the GP).
In Australia, anticoagulation clinics providing specialised
anticoagulation monitoring and management are offered in
some outpatient departments of major hospitals, and may be
led by clinicians or other health professionals (e.g., nurses,
pharmacists). Internationally, compared with usual care,
anticoagulation clinics have been shown to result in better
patient treatment satisfaction [267], as well as better quality
of anticoagulation control, lower rates of bleeding and
thromboembolic events, and lower healthcare costs [268].
In rural Australian settings, coordinated anticoagulation
management services—incorporating patient education,
point-of-care INR testing, patient self-care models, protocols
Table 5 Non-Vitamin K oral anticoagulants for prevention of emboli in atrial fibrillation—dose adjustments in
Australia.
NOAC Full dose Dose reduction Indications for dose reductions
Apixaban 5 mg bd 2.5 mg bd At least two of the following:
 aged 80 years or more
 weight 60 kg or less
 serum creatinine 133 mmol/L or more
Rivaroxaban 20 mg daily 15 mg daily CrCl 30–49 mL/min
and/or
combination with DAPT b
Dabigatran 150 mg bd 110 mg bd Aged 75 years or more
and/or
CrCl 30–50 mL/min
and/or
increased risk of major bleeding (e.g., combination with DAPT a)
bd, twice daily; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; NOAC, non-vitamin K oral anticoagulant.
aIf DAPT is required with anticoagulation and another indication(s) for dose reduction, consider using single antiplatelet therapy.
bIn patients receiving rivaroxaban who require antiplatelet therapy following stenting, consider early de-escalation to SAPT + OAC [297].
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and use of specially trained personnel (e.g., nurse, dietician
and pharmacist)—have been shown to increase time spent in
therapeutic range and to reduce complications related to
anticoagulation [269].
Published algorithms and guidelines are available to assist
dosage adjustments during the initiation and maintenance of
warfarin therapy, including response to over-anticoagulation
(cardiovascular therapeutic guidelines [270]).
6.3.1.1. Point-of-care International Normalised Ratio
Measurements for Patients Receiving Warfarin.
Recommendation: Point-of-care INR measurement is rec-
ommended in the primary care management of patients
receiving warfarin.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: Point-of-care devices using finger-prick capillary
blood sampling have enabled convenient and efficient mea-
surement of anticoagulation control in the practice setting or
the patient’s home. In addition, the mobility of point-of-care
testing enables multidisciplinary management of patients and
improves continuity of care. In Australia, practitioner-led
point-of-care INR testing for the management of patients with
AF has been trialled in general practices [271,272], outpatient
clinics [273], aged-care facilities [274], and community phar-
macies [275,276], as well as in conjunction with home-based
medicine review services led by accredited pharmacists [277],
across metropolitan or urban, [271,273,274,277–279], rural
[271,272,276,277], and remote [271,277] settings. Collectively,
Australian studies have shown that point-of-care INR mea-
surement is associated with improved INR control (i.e. pro-
portion of INR results within therapeutic range and time in
therapeutic range); a significant decrease in adverse clinical
events, including thrombosis, and minor and major haemor-
rhagic events; and significantly increased persistence with
warfarin therapy.
Resources and other considerations: In general, point-of-
care devices (and consumables such as testing strips) are
currently relatively expensive to purchase (in the absence
of Medicare rebates). Overall, they are generally cost effective
in terms of optimising related health outcomes [280]; how-
ever, this depends on the overall model of care in which the
devices are used [281]. Patients may be able to claim certain
costs against their own private health insurance. Some prac-
tices (e.g., medical centres and community pharmacies) may
offer point-of-care testing on a fee-for-service basis (includ-
ing package or subscription-based plans). Some local health
districts support the use of point-of-care INR testing, partic-
ularly within hospital-to-home or post-discharge liaison or
follow-up services.
Practice advice: Current point-of-care measurement of
coagulation parameters (e.g., INR) applies only to those
using warfarin therapy. Specific point-of-care coagulation
tests for the NOACs are not available. Only INR measure-
ment devices that are approved by Australia’s Therapeutic
Goods Administration (TGA) and those that have been dem-
onstrated to be accurate and precise should be used for point-
of-care testing, with appropriate procedures in place for
quality control and quality assurance, addressing device
operation, device calibration, and responding to aberrant
results [282,283]. All device users (health professionals,
patients, and carers) must be adequately trained in use of
the device. Hence, not all settings will be suitable for point-of-
care testing, particularly among self-monitoring patients (e.
g., those with poor cognition or comprehension skills, or poor
manual dexterity).
Although generally comparable [284,285], point-of-care
coagulometers are less consistent and tend to slightly over-
estimate the INR when measurements are above the thera-
peutic range (INR > 3.5) [286,287]. These devices may also
underestimate INR when measurements are below the ther-
apeutic range (i.e. INR  1.9) [288,289]. Measurements may
also be inaccurate in certain patients (e.g., severe anaemia,
antiphospholipid syndrome). Therefore, point-of-care testing
is most useful for the ongoing management of patients who
are generally stable and/or in acute situations where a timely
result is needed to guide patient management.
A range of guidelines and online or eHealth resources are
available to help guide both practitioners and patients in
point-of-care INR testing. They include computer decision
support software that can link INR results and automatically
recommend the patient’s next dose of warfarin.
6.3.2. Management of Bleeding
Recommendation: Symptomatic treatment with fluid
replacement or blood transfusion should be initiated for
all patients with moderate to severe bleeding while treat-
ment of the cause is addressed.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Factor replacement therapy with PCCs
can be considered for patients taking warfarin or specific
factor Xa inhibitors with life-threatening bleeding or those
requiring emergency surgery.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Weak.)
Recommendation: Idarucizumab is recommended for
patients taking dabigatran who experience life-threatening
bleeding or require emergency surgery.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Anticoagulant therapy should be
recommenced after bleeding has been addressed and when
the stroke risk is believed to exceed the risk of further
bleeding.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Rationale: General principles in the management of
patients bleeding while receiving anticoagulation have been
described in a consensus document developed by the Throm-
bosis & Haemostasis society of Australia and New Zealand
(THANZ, previously known as Australian Society of Throm-
bosis and Haemostasis) [290]. These principles are drug
discontinuation, baseline laboratory assessment (APTT, pro-
thrombin time [PT] and thromboplastin time [TT], drug
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levels and creatinine), general supportive care measures,
activated charcoal if patients present within four hours of
the last oral dose of NOAC and administration of a haemo-
static agent (see Figure 7).
Vitamin K can reverse the anticoagulant action of warfarin
but has delayed onset of activity. Prothrombin factor
concentrates (PCCs) were developed for the reversal of war-
farin; in Australia three-factor PCC (Prothrombinex-VF, CSL,
Melbourne) can be used for this purpose [291].
A second PCC, factor eight inhibitor bypassing activity
(FEIBA) has been evaluated for the prevention of life threat-
ening bleeding in patients on NOACs in laboratory and
Figure 7 Management of bleeding for non-vitamin K antagonist oral anticoagulant treated patients.
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animal studies. FEIBA appears to have a more consistent
impact on haemostatic changes associated with the NOACs
than other agents, but clinical data are limited.
FEIBA is not used for patients on warfarin and the efficacy
of three-factor PCC on reversing bleeding due to the NOACs
has not been evaluated [290,292].
Idarucizumab is a humanised specific monoclonal anti-
body fragment that binds dabigatran with high affinity. It
was shown to rapidly and completely inhibit the anticoag-
ulant activity of dabigatran in more than 90% of critically
ill patients who suffered uncontrolled bleeding or required
emergency surgery [293]. It has become available in
most hospitals in Australia and New Zealand since the
publication of the THANZ recommendations, and it
should be considered in patients meeting the criteria
above. It does not reverse the activity of any other antico-
agulant drug.
The resumption of OAC following interruption of treat-
ment because of GI bleeding is associated with decreased
mortality and no increase in bleeding, provided that the drug
is reintroduced 1 week following control of bleeding [294]. In
the Reversal Effects of Idarucizumab on Active Dabigatran
(RE-VERSE AD) study of idarucizumab, thrombotic events
occurred within 6 days after administration of the reversing
agent when anticoagulation was not reinitiated [293]. The
above recommendation to commence OAC within 1 week is
based on consensus opinion [295].
Practice advice: If major/life-threatening bleeding occurs,
the anticoagulant effects of warfarin can be reversed rapidly
with prothrombin factor concentrate, and more slowly with
administration of vitamin K. Similarly, if major/life threat-
ening bleeding occurs during treatment with a factor Xa
inhibitor (rivaroxaban or apixaban), supportive measures
and FEIBA can be considered (see Figure 7), because the
specific reversal agent for these agents (andaxanet) is not
yet approved for use in Australia.
For patients with major bleeding requiring a haemostatic
agent, the choice of specific agent depends on drug availabil-
ity and the experience of the centre, and should therefore be
made in consultation with a local haematologist.
6.3.3. Combining Anticoagulants and Antiplatelet
Agents
Recommendation: Careful assessment of the bleeding and
ischaemic risks (i.e. stroke, new or recurrent cardiac ischae-
mia or infarction, and stent thrombosis) should be under-
takenfor patientswithAFwhohavea long-term requirement
for anticoagulation for stroke prevention and require dual
antiplatelet therapy (DAPT) after acute coronary syndrome
(ACS) or stent implantation (or both).
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Duration of triple therapy (aspirin,
P2Y12 inhibitor and OAC) should be as short as possible
to minimise bleeding, while ensuring coverage of the ini-
tial period of high risk of stent thrombosis and/or recurrent
coronary ischaemia.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Where DAPT is required in combina-
tion with OAC, low-dose aspirin (100 mg) and clopidogrel
(75 mg) are recommended. Ticagrelor and prasugrel are not
recommended in this situation.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Where OAC is used for AF, discontin-
uation of antiplatelet therapy should be considered 12
months after stent implantation, ACS, or both, with con-
tinuation of OAC alone.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Weak.)
Rationale: Recent guidelines based predominantly on con-
sensus opinion have supported the use of combined antico-
agulant and DAPT in patients who require OAC for stroke
prevention, and DAPT following ACS or stent implantation,
or both. To minimise the risk of bleeding and maintain
effectiveness, it is recommended that the INR be kept
between 2.0 and 2.5 in patients on warfarin, and that the
doses of NOAC evaluated in the appropriate clinical trials be
used (see Table 5). Low-dose aspirin (100 mg) should be
used, and clopidogrel is favoured over ticagrelor or prasu-
grel as the second antiplatelet (see Figure 8). With regards to
down-titrating antiplatelet therapy, several trials published
in this area inform practice [296–298]. The What is the Opti-
mal Antiplatelet and Anticoagulant Therapy in Patients with
Oral Anticoagulation and Coronary Stenting (WOEST) trial
showed that clopidogrel and warfarin caused less bleeding
than triple therapy in patients undergoing stenting, and that
there was less recurrent ischaemia and mortality with this
strategy, although many of these patients did not have AF
[296]. The Open-label, Randomized, Controlled, Multicenter
Study Exploring Two Treatment Strategies of Rivaroxaban
and a Dose-adjusted Oral Vitamin K Antagonist Treatment
Strategy in Subjects with Atrial Fibrillation who Undergo
Percutaneous Coronary Intervention (PIONEER AF-PCI)
trial with rivaroxaban [297] and the Randomized Evaluation
of Dual Antithrombotic Therapy with Dabigatran Versus
Triple Therapy with Warfarin in Patients with Nonvalvular
Atrial Fibrillation Undergoing Percutaneous Coronary Inter-
vention (RE-DUAL PCI) trial with dabigatran [298] looked
exclusively at patients who had N-VAF and required OAC
for stroke prevention, but also required antiplatelet therapy
after stenting. Single antiplatelet therapy (SAPT)—predomi-
nantly clopidogrel, but some use of ticagrelor and prasu-
grel—and the NOAC (with specific dosing regimens:
dabigatran 150 mg or 110 mg bd, rivaroxaban 15 mg daily)
was shown to cause significantly less bleeding than triple
therapy, with no increase in ischaemic events, but none of
these trials was sufficiently powered to definitely prove this.
Also, these results were attained with dual therapy starting
several days after percutaneous coronary intervention in
both the PIONEER and RE-DUAL studies, irrespective of
the type of stent used. No recommendation regarding the use
of SAPT with apixaban can be made until the completion of
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the Apixaban Versus Vitamin K Antagonist in Patients With
Atrial Fibrillation and Acute Coronary Syndrome and/or
Percutaneous Coronary Intervention (AUGUSTUS) trial,
which will directly address the issue.
In a Danish nationwide study of AF patients with
stable coronary artery disease, the addition of antiplatelet
therapy to warfarin was found to be associated with an
increased risk of bleeding but no reduction in ischaemic
risk [299]. Thus, consideration should be given to stopping
antiplatelet therapy in anticoagulated patients 12 months
following an ACS or stent implantation [299,300] (see
Figure 8).
Figure 8 Combining anticoagulants and antiplatelet agents.
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Benefits and harms: When patients need to be treated with
OAC and DAPT there is always trade-off between prevent-
ing new or recurrent ischaemic events and bleeding. The
balance between these factors varies between individuals,
in that stent and lesion characteristics, location, patient
comorbidities, and concomitant medication can all influence
the risk vs. benefit equation [295]. In general, the duration of
triple therapy should be as short as possible, to reduce the
substantial risk of bleeding with this combination [15,301].
Practice advice: Patients who require long-term OAC for
stroke prevention in N-VAF but also require shorter-term
DAPT are difficult to manage; however, based on recent
studies [296–298] some practical advice can be provided.
Clopidogrel is the recommended second antiplatelet agent
[15,301], and using it with a NOAC [15] is generally preferred
to warfarin. The decision on duration of triple therapy
depends on the individual patient characteristics, balancing
the risk of ischaemia and the risk of bleeding. Bleeding scores
such as the HAS-BLED score [239], although not recom-
mended when deciding whether or not to use an anticoagu-
lant in a patient with AF at risk of stroke, may be of some
value in determining high risk of bleeding in patients in
whom irreversible factors are present and a shorter duration
of triple therapy may be considered. Recommendations
regarding optimal duration of therapy continue to evolve
[302]. In patients following elective stenting with newer-
generation drug-eluting stents, early cessation (within 1
week of stenting) of aspirin may be considered, with contin-
uation of single antiplatelet and OAC. In patients following
an ACS with or without stenting, a longer duration of triple
therapy (1–6 months) may be preferred. Further guidance
can be found in Figure 8.
One of the main concerns of triple therapy is the risk of GI
bleeding. There are no studies evaluating the benefit of
proton pump inhibitors in patients on combined antiplatelet
and anticoagulant drugs. However, PPIs reduce GI bleeding
in high-risk patients taking aspirin, and lower-risk patients
taking both aspirin and clopidogrel [303,304]. The risk of GI
bleeding in patients on triple therapy is therefore likely to be
reduced by concomitant administration of proton pump
inhibitors [303].
6.3.4. Anticoagulation in Special Situations
6.3.4.1. Anticoagulation in Patients with Atrial Fibrillation
and Chronic Kidney Disease.
Recommendation: The decision to use anticoagulants in
patients with AF and severe CKD (CrCl <30 mL/min)
should be individualised because there are no prospective
data showing benefit in this population.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Warfarin should be used if an AF
patient with severe CKD requires anticoagulant therapy.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Rationale: CKD increases the risk of both stroke and bleed-
ing in patients with AF [305]. Anticoagulation can be safely
used in patients with mild to moderate CKD (CrCl 30–60
mL/min), with a meta-analysis of the NOAC trials suggest-
ing fewer ischaemic or bleeding events on NOACs than on
warfarin [306]. Renal function should be regularly monitored
in AF patients on NOACs to ensure appropriate dose adjust-
ment (see Table 5).
There are no data from prospective randomised trials
evaluating the use of warfarin in patients with severe renal
impairment or those on dialysis (CrCl <30 mL/min). Also,
observational studies are conflicting, with some suggesting
benefit [307] and others harm [308]. Importantly, NOACs are
contraindicated in this population.
Practice advice: In patients with compromised renal func-
tion (CrCl 30–50 mL/min) renal function needs to be
assessed at least twice yearly, and more frequently if the
patient becomes unwell. The Cockcroft–Gault formula
should be used to calculate CrCl. Patients should be advised
to seek medical attention if they develop concomitant illness
that could further compromise renal function. The lack of
data showing benefit of anticoagulation in AF patients with
severe CKD or end-stage renal failure is not widely appre-
ciated by practising clinicians. At present, the decision to
anticoagulate these patients should be individualised with
the knowledge that an estimate of benefits and harms cannot
be provided.
6.3.4.2. Anticoagulation in the Older or Frail Patient.
Thromboembolic risk of stroke in N-VAF increases strongly
with increasing age, with a risk ratio of 1.4 per decade in
those aged more than 65 years [309]. However, clinicians are
traditionally hesitant to prescribe anticoagulant therapy in
older people (those aged more than 75 years) because of a
perceived increased risk of adverse events, in particular
bleeding if the patient falls (see Section 6.2.2) [310–312].
Patients with a high risk of falling do have increased risk of
ICH; however, they also have a high risk of ischaemic stroke,
and will benefit from anticoagulant therapy. Modelling has
indicated that older people would have to fall almost 300
times a year for the risk of traumatic ICH among patients on
warfarin to outweigh the benefits [313].
Data from registries indicate that the risk of bleeding
increases less with increasing age than the risk of stroke.
Thus, the net clinical benefit is in favour of treating older
people and those aged more than 85 years [314].
It is common practice to adopt aspirin over OAC in older
people because of a perceived lower bleeding risk. In the
small Birmingham Atrial Fibrillation Treatment of the Aged
(BAFTA) trial of patients with AF aged more than 75 years,
warfarin resulted in a halving of the incidence of stroke
relative to aspirin, whereas bleeding events were comparable
[315]. The use of OACs in a general practice RCT has dem-
onstrated safety and benefit in older people, including those
aged more than 85 years [315].
Subgroup analyses of the Rivaroxaban Once Daily, Oral,
Direct Factor Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial
in Atrial Fibrillation (ROCKET AF) and Apixaban for Reduc-
tion in Stroke and Other Thromboembolic Events in Atrial
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Fibrillation (ARISTOTLE) trials show that the superiority of
rivaroxaban and apixaban over warfarin is maintained in
older people [316,317]. Pharmacodynamic considerations
suggest that rivaroxaban and apixaban are preferable to
dabigatran in older people, due to decreasing renal function
with age. Although data from the Randomized Evaluation of
Long-Term Anticoagulation Therapy (RE-LY) study sug-
gested dabigatran has acceptable safety and efficacy in the
elderly when compared to warfarin [318,319], other cohort
studies [320–322] suggest an increased GI bleeding risk. More
research needs to be carried out to arrive at definite conclu-
sions about preference of one NOAC over the other in this
patient population. Dabigatran and rivaroxaban are contra-
indicated with a CrCl of less than 30 mL/min, whereas dose
reductions are possible with apixaban down to a CrCl of
25 mL/min. Given the prevalence of polypharmacy in older
people, these agents may also be preferable to warfarin;
however, missed doses, more common with increasing num-
bers of medications, may be more detrimental with NOACs
than with warfarin.
Practice advice: The combination of impaired hepatic,
renal, cognitive function, high-risk medications, and poly-
pharmacy make drug interactions and complications more
likely. Furthermore, these patients are usually excluded from
randomised trials and observational registries, so there are
few data to guide decisions. An integrated management
approach would be of particular value in this cohort (see
Section 7).
6.3.4.3. Anticoagulation in Aboriginal and Torres Strait
Islander peoples. There are many barriers to the optimal
medical management of Aboriginal and Torres Strait
Islander peoples with AF. The risk of all types of stroke is
three-fold higher than in the broader population [323], and
the ratio is higher in younger age groups. This is contributed
to by the increased burden of AF in Aboriginal and Torres
Strait Islander patients [8,324], resulting from high rates of
rheumatic heart disease and other cardiovascular diseases,
and the prevalence of other risk factors including obesity,
diabetes, hypertension, and CKD.
Stroke risk calculators have not been specifically tested or
adapted for Aboriginal and Torres Strait Islander peoples
with non-rheumatic AF. Making the assumption that these
calculators are applicable, one local audit suggested
that Aboriginal and Torres Strait Islander patients at
high risk of stroke are undertreated whereas low-risk
patients are overtreated, in a similar fashion to the general
population [325].
The need for regular monitoring of warfarin therapy pro-
vides additional challenges, particularly for the geographi-
cally isolated, and this can be eased by point-of-care testing,
which is unfortunately not available in all communities.
There are limited data on the use of NOACs in this popu-
lation, and the out-of-pocket costs of these drugs relative to
warfarin may be real disincentives to their use. However, the
lack of INR monitoring makes this an attractive treatment
option, although clinical monitoring is still important when
using NOACs.
Integrated care, with an emphasis on culturally appropri-
ate healthcare workers to facilitate patient-centred decision-
making, and coordinated outreach strategies that include
provision of specialist clinics and echocardiographic services
are currently inadequate because of shortfalls in the work-
force and funding; hence, they remain aspirational objectives
[326,327].
6.3.4.4. Bridging for Patients with Atrial Fibrillation
Undergoing Surgical Procedures.
Recommendation: Bridging with LMWH or UFH is not
necessary for warfarin treated patients at low to moderate
risk of stroke undergoing planned surgical intervention.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Bridging with LMWH or UFH is not
recommended for NOAC-treated patients.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Bridging with LMWH or UFH is indi-
cated for patients at very high risk of stroke (e.g., warfarin-
treated patients with mitral mechanical prosthetic heart
valves) undergoing planned surgical intervention.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: It has traditionally been standard practice to stop
warfarin 5 days before surgical procedures, and commence
parenteral heparin once the INR has fallen to a subtherapeu-
tic range while awaiting surgery (bridging). The Bridging
Anticoagulation in Patients Who Require Temporary Inter-
ruption of Warfarin Therapy for an Elective Invasive Proce-
dure or Surgery (BRIDGE) trial evaluated this strategy in AF
patients receiving warfarin with at least one risk factor for
stroke (but no recent stroke or TIA) undergoing non-cardiac
surgical procedures [328]. The mean stroke risk score of this
cohort was CHADS2 of 2.3, equivalent to a CHA2DS2-VA
ranging from 2 to 5. Bridging was associated with increased
bleeding but no protection against stroke when compared to
stopping warfarin without bridging anticoagulation. This
finding was supported by a subsequent meta-analysis
[329], and bridging is no longer recommended in this popu-
lation of patients. Bridging for patients at higher risk of stroke
(e.g., CHA2DS2-VA > 5) undergoing surgical procedures
should be evaluated on a case-by-case basis.
Heparin bridging is not required in patients receiving
NOACs because of the short half-lives of these therapies.
Each of the large RCTs of these therapies has reported com-
parable bleeding and embolic events between warfarin and
NOACs in patients undergoing surgical procedures in whom
therapy was usually interrupted [330–332].
In general, the NOAC can be omitted for 24 hours in
patients with normal renal function undergoing a low bleed-
ing risk surgical procedure, and for 48–72 hours if renal
function is impaired or the bleeding risk of the surgery is
high.
For procedures in which haemostasis is immediate post-
operatively, anticoagulation can be recommenced 6–8 hours
following the procedure. More generally, NOACs can be
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commenced 24 hours following low bleeding risk procedures
or 48–72 hours for procedures with higher bleeding risk. It is
recommended that the decision on timing of postoperative
anticoagulation be made in conjunction with the involved
proceduralist or surgeon.
Practice advice: Bridging is still recommended in patients
with mitral mechanical valve replacements requiring warfa-
rin cessation for surgical procedures. The BRIDGE trial
included few patients at high embolic risk, and patients with
strokes or TIA within the preceding 12 weeks were excluded
[328], thus bridging may still be considered in these patients
if receiving warfarin.
6.3.4.5. Anticoagulation for Patients Undergoing Invasive
Coronary Procedures
About 20% of patients with AF will require some form of
coronary intervention over time [333]. In general, non-urgent
catheterisation should be delayed until anticoagulation sta-
tus and renal function are known. Recommendations for
periprocedural management of anticoagulation in these
patients pertain to those who are on OAC at the time of their
presentation; the recommendations are guided by consensus
opinion [334]. Specific factors known to reduce bleeding
complications should be implemented (radial access and
use of small-diameter sheaths). Several case series have sug-
gested that it is safe to continue warfarin through the angio-
graphic procedure [335,336]. There are no randomised
studies evaluating this, but extrapolation from the BRIDGE
study suggests this to be reasonable practice.
Because of the shorter half-lives of the NOACs, these
agents can be withheld 24 hours before the procedure in
patients with normal renal function and 48–72 hours in those
with impaired renal function, without bridging therapy. The
NOAC can be recommenced at the scheduled time post-
procedure. In stented or ACS patients requiring DAPT, doses
of NOAC should be as recommended in Table 5
6.3.4.6. Anticoagulation for Cardioversion.
Recommendation: Anticoagulation is recommended at the
time of electrical or pharmacological cardioversion, and for
at least 4 weeks post-procedurally.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Anticoagulation for 3 weeks or a
transoesophageal echocardiogram (to document absence
of LA thrombus) is recommended before cardioversion
in patients with more than 48 hours or an uncertain dura-
tion of AF.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Rationale: Clinical cardioversion of AF may be achieved by
electrical or chemical means. The associated risk of throm-
boembolism (leading to stroke or systemic embolism) is high,
both at the time of the cardioversion and for some weeks
afterwards [337,338]. This risk is independent of the mode of
arrhythmia termination, and is more strongly related to the
duration of the preceding period of AF as well as to attendant
risk factors. In a recent large series of patients who were not
anticoagulated for cardioversion, those with heart failure and
diabetes had a very high (9.8%) thromboembolic risk within
the 30-day period afterwards [337].
In those patients who have a likely duration of arrhythmia
onset of more than 48 hours, or in those in whom the time of
onset is uncertain, therapeutic anticoagulation for at least 3
weeks is required, to ensure the resolution of any attendant
LA thrombus that may be present. Alternatively, TOE may be
used to exclude the presence of LA thrombus [339]. LA
thrombus most commonly forms within the LA appendage,
often in the setting of poor LA appendage contractility
caused by AF. The stasis caused by this reduced emptying
of the appendage may result in spontaneous echocardio-
graphic contrast being visible on TOE. The presence of spon-
taneous echocardiographic contrast is not a contraindication
to cardioversion [340].
It must be stressed that a reassuring TOE documenting the
absence of thrombus at the time of cardioversion does not
obviate the need for anticoagulation in the post-procedural
month, and potentially indefinitely following that, depend-
ing on thromboembolic risk factors. Recent data with NOACs
indicate the ease, efficacy, and safety of use of these agents for
cardioversion [341–343]. The rapid onset of full anticoagula-
tion effect with these agents eliminates the requirement for
bridging with heparin or LMWH until a therapeutic INR is
achieved in those patients anticoagulated with warfarin.
Although data from RCTs are lacking, it is reasonable for
patients with lone AF (without thromboembolic risk factors)
and a known arrhythmia onset time within 48 hours prior, to
undergo cardioversion without administering 1 month of
periprocedural anticoagulation. However, determining the
arrhythmia onset time may be difficult and imprecise in all
but the youngest and most symptomatic paroxysmal AF
patients. Patients with established, ambient AF may develop
a sudden onset of symptoms when adrenergic factors lead to
a precipitant onset of rapid ventricular response. Where there
is any doubt, the periprocedural anticoagulation recommen-
dations outlined above should be followed. See Figure 2 for
more information.
6.3.4.7. Anticoagulation for Catheter Ablation Procedures.
Recommendation: Uninterrupted oral anticoagulation is
recommended for patients undergoing catheter ablation.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: Pulmonary vein isolation is associated with a risk
of serious bleeding. Tamponade rates have been reported to
be 1.3% internationally, although they are thought to be
lower in Australian practice [344]. On the other hand, endo-
cardial ablation constitutes a prothrombotic insult, so rela-
tively high levels of anticoagulation are mandated during the
procedure. There has been a shift towards performing abla-
tion on uninterrupted anticoagulant therapy following the
randomised Role of Coumadin in Preventing Thromboem-
bolism in Atrial Fibrillation (AF) Patients Undergoing Cath-
eter Ablation (COMPARE-AF) trial (n = 1584), which showed
that warfarin discontinuation increased the incidence of peri-
procedural stroke and minor bleeding when compared with
uninterrupted therapy [345].
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Subsequently, two RCTs have compared uninterrupted
NOAC with uninterrupted warfarin therapy in patients
undergoing catheter ablation [346,347]. The small Study
Exploring Two Treatment Strategies in Patients with Atrial
Fibrillation Who Undergo Catheter Ablation Therapy (VEN-
TURE-AF) (n = 250) compared rivaroxaban (20 mg once
daily) against warfarin. It found low event rates in both arms
and no difference in the incidence of embolic or ischaemic
events between the two groups [347]. The Randomized Eval-
uation of Dabigatran Etexilate Compared to Warfarin in
Pulmonary Vein Ablation: Assessment of an Uninterrupted
Periprocedural Anticoagulation Strategy (RE-CIRCUIT) trial
(n = 704) reported significantly fewer bleeding events in
patients randomised to dabigatran 150 mg bd than patients
receiving warfarin, although again, the absolute number of
events was small [346].
Practice advice: In addition to the body of data from RCTs
supporting their use, it is recommended that uninterrupted
warfarin or dabigatran be used preferentially as the OAC for
patients undergoing catheter ablation because agents are
available to rapidly reverse the anticoagulant action of both
drugs. For patients taking apixaban or rivaroxaban, lack of a
reversing agent dissuades many operators from performing
the procedure on uninterrupted OAC. One frequently
adopted strategy is minimally interrupted OAC (i.e. with-
hold one or two doses prior to the procedure). Although not
evaluated in randomised trials, this practice appears to min-
imise the risk of bleeding without exposing the patient to
prolonged risk of thrombosis [348].
6.3.4.8. Anticoagulation in Patients with Hypertrophic
Cardiomyopathy
The mechanistic and clinical differences between the general
population and HCM patients preclude the use of stroke risk
scores [349]. Given the significantly increased risk of throm-
boembolic events (incidence of 3.8% annually [194]), anti-
coagulation is recommended in all HCM patients who
develop AF [196,200,350]. Limited data exist for the use of
NOACs, but observational studies suggest that their use can
be safe and effective in HCM patients with AF [351,352].
6.3.4.9. Anticoagulation in Grown-up Patients with Con-
genital Heart Disease
GUCH with atrial arrhythmias have a higher risk of atrial
thrombo-emboli and should be considered for oral antico-
agulation [353]. In patients undergoing cardioversion, in
particular cyanotic CHD, a TOE should be considered (see
Section 6.3.4.6). There is lack of evidence for the NOACs in
this population. Warfarin and LMWH are therefore the main-
stay for long-term anticoagulation.
6.3.4.10. Anticoagulation in Athletes
Anticoagulation strategies, although rarely required due the
typically low CHA2DS2-VA score among healthy athletes,
should follow standard guidelines. However, additional con-
sideration may be warranted for athletes participating in
high-impact sports, where bleeding risk may be elevated.
6.3.4.11. Anticoagulation in Post-operative Atrial Fibrillation
Postoperative AF occurs in about 3% of patients undergoing non-
cardiac surgery [354], and while most revert to sinus rhythm, the
occurrence of AF in this context is associated with an increased risk
of stroke both within 30 days and in the long term [355]. In patients
for whom AF persists for more than 48 hours, long-term antico-
agulation practice should be the same as for those who have not had
surgery [356].
Although AF is more common following cardiac surgery,
occurring in up to 30% of patients, the majority have reverted
to sinus rhythm by 6 weeks. Observational studies have
suggested the long-term stroke risk is less that that observed
for the NVAF population, and comparable to patients who
undergo CABG without developing AF [357].This suggests
that many of these patients may not require long-term
anticoagulation.
6.3.5. Stroke Prevention with Left Atrial Appendage
Occlusion and Exclusion
Recommendation: LAA occlusion may be considered for
stroke prevention in patients with N-VAF at moderate to
high risk of stroke and with contraindications to oral anti-
coagulation therapy.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
6.3.5.1. Percutaneous Left Atrial Appendage Occlusion.
There have been two randomised trials of percutaneous
LAA occlusion compared with warfarin [358,359]. A meta-
analysis of these two trials and their respective registries
showed no difference in the incidence of stroke or systemic
embolism, or in major bleeding between the two groups.
There are no randomised trials comparing LAA occlusion
to standard therapy in patients with contraindications to
anticoagulation. Extrapolation from the RCTs of LAA occlu-
sion compared with warfarin [358,359] have provided indi-
rect evidence that LAA closure improved some clinical
outcomes when compared with placebo [360]. These findings
indicated that LAA closure reduced cardiovascular or unex-
pected death and all-cause stroke by a statistically significant
amount.
With regards to acute procedural complications of LAA
occlusion device implantation, among 1021 patients who
were included in the EWOLUTION: Design of a Registry
to Evaluate Real-world Clinical Outcomes in Patients with
AF and High Stroke Risk-treated with the WATCHMAN Left
Atrial Appendage Closure Technology register [361], 3.6%
(95% CI: 2.5%–4.9%) of patients experienced a serious pro-
cedure or device adverse event within 30 days of the proce-
dure. Event rates were comparable between those ineligible
and those eligible for an OAC (2.2% and 3.8%, respectively,
p = 0.129). However, a recent European survey detected
complication rates considerably higher than this [362].
Resources and other considerations: Economic modelling
in the Australian context has suggested that use of the LAA
occlusion device in appropriate populations will result in an
incremental cost-effectiveness ratio (ICER) of about $28,000
per QALY, based on a plausible extrapolated incremental
survival gain of 10 years or more. This is regarded as accept-
ably cost effective for the proposed high clinical need popu-
lation [360].
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Practice advice: Percutaneous LAA occlusion should be
limited to patients at high risk of stroke in whom anticoa-
gulation is contraindicated, see Figure 6.
6.3.5.2. Surgical Left Atrial Appendage Occlusion.
Recommendation: Surgical occlusion or exclusion of the
LAA may be considered for stroke prevention in patients
with AF undergoing cardiac surgery.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Rationale: A recent meta-analysis that collated the key
pieces of evidence from the literature pertaining to LAA
occlusion in cardiac surgery reported that the incidence of
post-stroke was significantly reduced in the LAA occlusion
group compared with the LAA preservation group (1.4%
versus 4.1%; odds ratio [OR]: 0.48; 95% CI: 0.24–0.98;
p = 0.04) [363]. However, a large observational study that
followed almost 10,000 patients after having cardiac surgery
(CABG or valve repair or replacement) was recently pub-
lished. It presented results suggesting that LAA closure
during routine cardiac surgery did not significantly influence
the risk of stroke or long-term mortality [364].
Incomplete LAA occlusion can increase stroke risk; there-
fore, continued anticoagulation is recommended unless com-
plete occlusion is confirmed, generally by TOE [365].
Practice advice: Various surgical methods can be used to
occlude the LAA during cardiac surgery; e.g., sutures, sta-
ples, ligation, resection, and LAA clip devices. Any possible
differences in safety and efficacy of the different surgical
techniques are currently unknown. Therefore, surgeons
should perform the LAA occlusion technique with which
they have the most experience.
6.3.6. Secondary Stroke Prevention
Recommendation: Early initiation of anticoagulants in the
first few days after an ischaemic stroke is not recommended
because of the risk of haemorrhage or haemorrhagic trans-
formation of infarction.
(GRADE quality of evidence: High; GRADE strength of rec-
ommendation: Strong.)
Recommendation: For ischaemic stroke patients, the
decision to begin OAC can be delayed for 2 weeks but
should be made before discharge.
(GRADE quality of evidence: Very low; GRADE strength of
recommendation: Weak.)
Recommendation: Early commencement of anticoagu-
lants may be considered after TIA or in mild stroke where
the risk of haemorrhage is determined to be low.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Weak.)
Rationale: For ischaemic stroke and TIA patients with par-
oxysmal or chronic AF, oral anticoagulation is recommended
for long-term secondary prevention.
The large International Stroke Trial (IST) [366] and Chinese
Acute Stroke Trial (CAST) [367] studies reported no clinical
advantage to early commencement of heparin following
ischaemic stroke. A reduction in recurrent ischaemic strokes
was offset by increased haemorrhagic stroke, and heparin
was associated with an excess of transfused or fatal extracra-
nial bleeds, especially at higher heparin doses. There was no
advantage in death or dependence at 6 months. In a meta-
analysis of early parenteral anticoagulants [368], there was
non-significant reduction in recurrent stroke in 7–14 days, a
significant increase in symptomatic intracranial bleeding,
and a similar rate of death or disability compared with other
treatments (aspirin or placebo).
The major NOAC trials have specifically delayed random-
isation beyond the early post-stroke period. Nonetheless,
based on the available data for parenteral drugs, beginning
any anticoagulants (e.g., therapeutic heparin, fractioned hep-
arin, warfarin, or NOAC) in the first days after stroke is likely
to be associated with a small or insignificant reduction in
recurrent stroke and a significant increase in symptomatic
haemorrhage.
Practice advice: Care is required if commencement of anti-
coagulation is delayed to after discharge, to ensure timely
follow-up for anticoagulation commencement.
Early commencement of anticoagulants should be consid-
ered following a TIA where the lack of tissue evidence of
stroke is expected to lower the risk of intracranial bleeding.
The Stroke Foundation additionally recommends that anti-
coagulation be commenced urgently after TIA, at 5–7 days
after moderate stroke and at 10–14 days after severe stroke,
acknowledging a lack of evidence for these recommenda-
tions and that timing of commencement of anticoagulation
after stroke is complex and based on the perceived risk
balance between haemorrhagic transformation of the infarct
and recurrent embolic stroke [83]. The early recommence-
ment of anticoagulants after ischaemic stroke may be guided
by estimated risk of stroke recurrence, repeat imaging, and
considering the consequences of haemorrhagic conversion in
the posterior fossa.
Forrecommendationsregarding screening for AF inpatients
with embolic stroke of uncertain source, see Section 4.4.3.
7. Integrated Management
Recommendation: An integrated care approach is recom-
mended; such an approach aims to provide patient-centred
comprehensive treatment delivered by a multidisciplinary
team.
(GRADE quality of evidence: High; GRADE strength of rec-
ommendation: Strong.)
Rationale: The rapidly increasing prevalence of AF has
placed a significant burden on healthcare use in Australia,
challenging the delivery of health services, and resulting in
care that is consequently more fragmented. There is a clear
need for more integrated care to support the comprehensive
treatment required, and to address the specific needs of
people with AF.
Integrated care is defined as a collaborative, patient-cen-
tred approach to the provision of healthcare that focuses on
improving patients’ experiences, health outcomes, and qual-
ity of life, while creating efficiencies in the health system. It
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requires access to, and coordination of, health services at all
levels of care; seamless communication and transitioning of
care across settings; effective use of available resources; use
of expertise across all health disciplines; support for patient
and carer engagement in their care; and application of evi-
dence-based strategies. The goal is to provide effective, effi-
cient, holistic, and comprehensive treatment that is tailored
to the individual patient’s values and preferences, focusing
on those with chronic conditions and multi-morbidities, and
recognising the multidimensional needs of this population.
In the context of AF, there is a need to particularly focus on
three fundamental aspects (see Figure 9):
 multidisciplinary teams, recognising the important roles of
GPs, other medical specialists, nurses, Aboriginal and
Torres Strait Islander health practitioners or workers,
and allied health professionals;
 patient-centred care with a focus on patient education, self-
management, shared decision-making and caregiver
involvement;
 application of eHealth to support AF management.
These fundamental aspects drive the comprehensive treat-
ment approach needed in the management of AF, which
comprises a range of interventions targeting the arrhythmia
itself, as well as risk factors and complications (see Figure 9).
These interventions may be multimodal in nature, involving
pharmacotherapy, specific procedures (invasive and non-
invasive) and lifestyle strategies, delivered as part of acute
or long-term management. Given the dynamic nature of AF,
the interventions required in any individual patient may
change over time, and therefore a core requirement of inte-
grated care is coordination, including the need for regular
review and risk assessment, with clear communication of the
treatment goals and care plans to patients, carers, and all
members of the healthcare team. Importantly, these must be
delivered alongside interventions that support patient adher-
ence to the treatment plan. Furthermore, there is a need to
understand the specific and unique challenges of the target
AF patient population in Australia, including Aboriginal and
Torres Strait Islander peoples (Section 6.3.4.3), those from
non-English speaking backgrounds, those from lower socio-
economic groups, those from regional and remote commu-
nities, and older or frail patients (Section 6.3.4.2).
To date, several structured and integrated approaches to AF
care have been developed [11]. Integrated AF management in a
European RCT increased the use of evidence-based care, and
reduced by one-third the composite outcome of cardiovascular
hospitalisation and cardiovascular death over a mean follow-
up of 22 months (14.3% vs 20.8%; HR: 0.65; 95% CI: 0.45–0.93;
p = 0.017) compared with usual care in a large tertiary care
centre [369]. Moreover, integrated AF management appeared
cost effective in that study [370]. However, an Australian RCT
showed no significant difference in rates of unplanned admis-
sions and death, although patients in the integrated care arm
were alive and/or out of hospital for significantly more days
[371]. Integrated AF care is likely to require different designs in
different healthcare settings.
In the Australian context, there are existing opportunities
and resources to support integrated care, including:
 access to multidisciplinary expertise (e.g., allied health
services, nurse practitioners, accredited pharmacists) via
Medicare-funded care plan referrals, multidisciplinary
case conferences, medication management reviews, and
health assessments for Aboriginal and Torres Strait
Islander peoples and older persons;
 initiatives to support the adoption of eHealth in general
practice (e.g., the Medicare-funded Practice Incentives Pro-
gram eHealth incentive);
 online systems to facilitate safe, effective, and efficient
communication between patients, clinicians, and health
practitioners around the care plan and provision of care
(e.g., the My Health Record and Healthcare Identifiers
systems);
 collaboration with consumer groups and patient advocates
for broader patient and community engagement, particu-
larly around health promotion, education, liaison and peer
support;
 local evidence-based guidelines to inform best practice;
 access to written and online information and resources for
consumers (patients and carers).
7.1. Multidisciplinary Teams
Many of the components of care for individuals with AF
require input from multidisciplinary healthcare professionals.
A multidisciplinary care team has been defined as ‘‘a team
comprising diverse health care professionals who communi-
cate regularly about the care of a defined group of patients and
participate in that care on a continuing basis” [372]. Effective
team-based chronic illness programs for conditions such as AF
often include the following strategies [373]:
 population-based care, which tries to ensure that effective
interventions reach all the patients that need them;
 treatment planning, in which formal written plans help
organise the work of teams and patients to navigate the
health system;
 evidence-based clinical management;
 self-management support, which emphasises both skills
and knowledge, and boosts motivation and confidence;
 more effective consultations, which are structured and
have sufficient time allocated;
 sustained follow-up.
Key elements for building effective teams include defined
goals; clinical and administrative systems; definitions of
tasks and division of labour; education and training; and
communication structures and processes [374].
There is some evidence that integrated and skilled AF
healthcare teams may offer efficient methods of optimising
care for individuals with AF in the outpatient setting
[369,371,375]. Roles and responsibilities should be defined
so that important investigations such as measuring thyroid
function are not overlooked, and so that key management
decisions (e.g., rate and rhythm control) are clearly
Australian Atrial Fibrillation Guidelines 2018 1249
communicated to the patient, their family and all members of
the multidisciplinary team.
Given the high population prevalence of AF and the fact
that it most often occurs in the context of multimorbidity,
there is a need for widely available generalist health ser-
vices—in particular, general practice—to have a major role in
the care of AF. General practice has a key role in screening,
case finding, diagnosis, and management including medical
specialist and allied health referrals and ongoing monitoring
and follow-up.
Each health discipline offers a unique lens to optimising
care for AF and each of the health disciplines actively
Figure 9 Fundamentals of integrated care in the management of atrial fibrillation.
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contributes to achieving comprehensive AF treatment.
Importantly, each may have a role in leading the healthcare
team or in care management in the outpatient setting.
Practice advice: Australia’s health system provides some
support for access to health services and treatments via the
government-funded Medicare program (including the Phar-
maceutical Benefits Scheme). Within this, there are increasing
opportunities to provide comprehensive, multidisciplinary
care tailored to individual AF patients; e.g., under the
Chronic Disease GP Management Plans and Team Care
Arrangements. Aboriginal and Torres Strait Islander patients
require multidisciplinary care, which may need to be deliv-
ered outside the GP practice model, involving Aboriginal
health workers, cardiac nurse coordinators, primary care
practitioners, and family members all working together with
specialists. Careful consideration and explanation is essential
for optimal management, especially in remote areas.
7.2. Patient-centred Care
Recommendation: Targeted patient education is recom-
mended throughout the continuum of AF management.
(GRADE quality of evidence: High; GRADE strength of rec-
ommendation: Strong.)
Recommendation: Shared decision-making should con-
sider patients’ beliefs, values, and preferences, with a goal
of empowering patients to undertake self-management.
(GRADE quality of evidence: Moderate; GRADE strength of
recommendation: Strong.)
Recommendation: Treatment goals should be developed
in partnership with patients, and communicated with all
members of the multidisciplinary team.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Rationale: A fundamental aspect of integrated care is to
organise the care following a patient-centred approach. This
includes active patient involvement and engagement in their
care process, as well as comprehensive education to prepare
patients for informed and shared decision-making and self-
management of their condition. Care should be responsive to
the preferences, values, and beliefs of the individual patient as
well as based on the best available evidence [376]. An expla-
nation of the patient’s role and vital contribution to the care
process may result in improved responsibility and the patient
taking ownership and self-managing the condition [377].
To prepare patients to take on such roles, it is important to
continuously provide education and instruction on the con-
dition, symptoms, therapy and possible complications, and
when to contact healthcare services in case of worsening
symptoms or an emergency situation [378]. Autonomous
and empowered patients are likely to participate in deci-
sion-making, which potentially improves the uptake of the
therapy, on the basis of shared accountability [379]. How-
ever, educational background and cultural diversity should
always be taken into account because these factors may
influence this process significantly.
Practice advice: Besides a central role for patients, it is
recommended to involve family and informal caregivers in
order to support patients in their self-management. For
Aboriginal and Torres Strait Islander peoples, a patient-cen-
tred approach particularly requires cultural awareness, sen-
sitivity, and safety, alongside engagement of family members
and the wider community, to build respectful and sustained
partnerships in care.
The role of community groups and patient advocates is
important to ensuring patient involvement, particularly in
terms of increasing public awareness about AF (including
existing health services and resources), and engaging with
policymakers to ensure that patients have access to treat-
ments and services.
7.3. eHealth to Support Atrial
Fibrillation Management
Recommendation: eHealth tools and resources should be
used by patients and health professionals, to support the
integrated management of AF.
(GRADE quality of evidence: High; GRADE strength of rec-
ommendation: Strong.)
Rationale: The term ‘eHealth’ refers to the use of electronic
media (e.g., web-based interfaces) or other technology (e.g.,
computerised tools and digital resources) to support the
provision of care to an individual.
eHealth can be used across all stages of the disease-man-
agement pathway, from screening and diagnosis, to decision-
making around treatment selection, to ongoing therapeutic
monitoring and management [380,381]. Furthermore,
eHealth has enabled components of AF care to be offered
in a wide range of practice settings, including community
pharmacies, nurse-led clinics, and home-based services. In
Australia, this technology may also support the implemen-
tation of outreach and telehealth services, providing access to
care in regional settings and where many Aboriginal and
Torres Strait Islander peoples reside.
Overall, the results from initial and pilot studies are
encouraging in terms of increasing the detection of AF cases
through mobile ECG devices [63,382–385]; optimising the use
of antithrombotic therapy for stroke prevention in AF via
computerised decision support [386–388]; improving the
time in therapeutic range for patients using warfarin via
point-of-care monitoring of anticoagulation; increasing
adherence to cardiovascular pharmacotherapy via smart-
phone text messaging [389–391]; and increasing access to
information for patients and their carers [392–395].
Practice advice: Given the cultural diversity in Australia, it
is an issue that many eHealth interventions currently provide
information and instructions only in English. Furthermore,
since most AF patients are older adults, health professionals
must first gauge their digital literacy before delivering eHealth
interventions. Health professionals are also responsible for
ensuring that they refer their patients to appropriate web-
based resources [396] and smartphone applications [397], so
that poor-quality or imbalanced information from potentially
biased sources does not undermine patients’ engagement in
shared decision-making and adherence to medicines.
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7.4. Medication Adherence and
Persistence to Atrial Fibrillation
Pharmacotherapy
Recommendation: All patients prescribed pharmacother-
apy for the management of AF, including core rhythm
control and anticoagulation therapies, should have their
treatment adherence and persistence regularly monitored
and supported using accessible and patient-centred strate-
gies.
(GRADE quality of evidence: Low; GRADE strength of rec-
ommendation: Strong.)
Rationale: Following an increased focus on the manage-
ment of AF, the use of specific pharmacotherapies appears to
have increased in Australia. This is particularly true for the
use of antithrombotics, following the availability of
NOACs—and their cost-subsidisation under the Pharmaceu-
tical Benefits Scheme—as alternatives to warfarin [398].
Although access to treatment options has assisted the
initial decision to prescribe therapy, optimal treatment out-
comes depend heavily on a patient’s adherence (i.e. the
extent to which a patient acts in accordance with the pre-
scribed interval, and dose of a dosing regimen [399]) and
persistence (i.e. the duration of time from initiation to
discontinuation of therapy [399]) with it. Poorer adherence
and/or persistence to anticoagulant therapy (whether war-
farin or NOAC) is associated with worse clinical outcomes
[400], especially in those at higher risk of stroke (i.e.
CHA2DS2-VASc score 2) [401]. Adherence to warfarin is
reported to range from 32.3% [402] (using the medication
possession ratio) to 67.7% [403], with persistence ranging
from 44.8% [404] to 77.2% [405]. Data on adherence to
NOACs are limited, but similar variations in adherence
and persistence are reported [406,407]. The literature con-
sistently reports that long-term persistence to any of the
anticoagulants tends to decrease over time, which is of most
concern in this population where the risk of stroke is likely
to increase over time. Real-world persistence is lower than
reported in clinical trials, with only a small proportion of
discontinuations explained through switching to alternative
anticoagulants [406]. Approximately one-third to half of
patients discontinue therapy within 2–2.5 years of initiation
[406,408]; 15% of patients fail to even collect their first repeat
prescription for therapy [409]. Patients’ perspectives must
be incorporated into the decision-making process for anti-
coagulant selection to obtain optimum adherence and per-
sistence [410].
Among the broader non-AF literature, meta-analyses have
shown that medication adherence interventions can lead to
significant, albeit modest, improvements in patient-centred
outcomes. Medicines self-monitoring and self-management
programs appear to be generally effective but may not be
suitable for all patients. Interventions such as simplification
of dosing regimens and interventions, pharmacist-led med-
icines management, care plans, and structured follow-up
have also been shown to be beneficial. Unfortunately, the
most effective interventions are usually complex (comprising
tailored ongoing support, cognitive behavioural therapy,
motivational interviewing, education, or daily treatment
support; which are delivered face-to-face, often via pharma-
cists) and may be difficult to implement in real-world prac-
tice [411]. More recent findings show the benefits of focusing
on interventions on behavioural strategies (e.g., habit-based
interventions), in preference to cognitive strategies targeting
knowledge and beliefs [412]. Additionally, attention to the
use of decision aids is needed, given that people exposed to
decision aids tend to feel more knowledgeable, better
informed, and clearer about preferences, translating to a
more active role in decision-making, which is likely to pro-
mote treatment adherence [413].
Studies evaluating interventions to specifically improve
adherence or persistence to AF pharmacotherapy are limited.
Recent studies focus on improving adherence to anticoagu-
lants via the use of electronic applications (see Section 7.3)
(one study with additional pharmacist-led patient educa-
tion), with mixed results. Earlier studies focused on educa-
tional and behavioural interventions, but did not generate
enough evidence to determine their impact [414]. No recent
studies have focused on promoting adherence to antiarrhyth-
mic therapies.
There are training resources available to support health
professionals in effectively and efficiently improving medi-
cation adherence [415]. A range of additional Australian
resources may be obtained from the NHFA, the National
Stroke Foundation, and the National Prescribing Service
(NPS) MedicineWise.
In addition, many community pharmacies in Australia are
accredited to provide appropriate support services, as
funded under the Sixth Community Pharmacy Agreement
between the Australian Government and the Pharmacy
Guild of Australia:
 Home Medicines Review and Residential Medication
Management Review;
 MedsCheck;
 Dose Administration Aid (DAA) service delivery;
 QUMAX (Quality use of medicines maximised for Aborig-
inal and Torres Strait Islander peoples).
8. Quality Indicators and
Research Priorities
8.1. Quality Indicators
The development of quality indicators facilitates the moni-
toring of quality of care, which in turn accelerates the trans-
lation of evidence into practice. In Australia, the use of these
measures is in its infancy in cardiovascular disease. A clinical
care standard for ACS has been developed by the Australian
Commission on Safety and Quality in Health Care, and is
accompanied by suggested quality indicators to facilitate
audit of adherence with this standard [416]. To date, no
standard or indicators have been developed for AF in
Australia. It is envisaged that these ACS indicators serve
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as suggestions for those healthcare services and practices that
wish to monitor the care of their patients with AF.
The development of these indicators followed two princi-
ples: adherence with each measure should improve care for
patients with AF, and information on adherence with each
measure can be readily obtained from the clinical record. The
suggested quality indicators for AF (listed below) were gen-
erated following review of the recommendations in these
guidelines and informed by those used internationally
[417]. Further research is required to evaluate the impact
of quality indicators in AF on patient outcomes. One Japa-
nese study showed that adherence with United States
defined performance measures derived from indicators
was associated with improved quality of life in patients with
AF [418]. Measures are divided into those to be used by
hospitals and outpatient services treating patients with a
new diagnosis of AF, and those to be used by those clinicians
managing patients with chronic AF in the outpatient setting.
Suggested quality indicators for investigation and man-
agement of patients with a new diagnosis of AF are:
 echocardiogram performed;
 rate versus rhythm strategy documented;
 CHA2DS2-VA score documented;
 prescription of anticoagulation for patients with a
CHA2DS2-VA score of more than 1;
 documented discussion and shared decision-making in
patients with a CHA2DS2-VA score of more than 1 who
are not anticoagulated.
Suggested quality indicators for the management of
patients with chronic AF are:
 CHA2DS2-VA score is documented annually for low-risk
patients who are not anticoagulated;
 monthly INR monitoring for patients on warfarin.
8.2. Research Priorities
Certain areas have been identified as priorities for future
research in AF, either because they are felt to be important
to augment the quality of evidence guiding existing re-
commendations, or because they will guide future recom-
mendations. Some of these studies have been initiated
and their results are anticipated at the time of writing.
The areas are:
 further studies to understand the stroke risk of brief dura-
tions of AF detected following screening of asymptomatic
patients;
 comparison of percutaneous catheter AF ablation and
AAD on the outcomes of death, stroke, or systemic embo-
lism in patients without heart failure;
 trials of anticoagulation compared with no anticoagulation
in patients with implanted atrial sensing devices and
AHREs of less than 24 hours (e.g., 5–24 hours);
 comparison of single antiplatelet therapy versus DAPT in
anticoagulated AF patients with ACS and/or stenting
powered for ischaemic outcomes of stroke, myocardial
infarction, or cardiac death;
 studies of surgical LAA occlusion compared with no occlu-
sion in patients with AF undergoing CABG powered for
the outcomes of stroke and death;
 studies to address the predictive value of the CHA2DS2-
VA score in Aboriginal and Torres Strait Islander patients;
 barriers to anticoagulation in Aboriginal and Torres Strait
Islander patients;
 trials of anticoagulation in AF patients with severe CKD.
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11. Appendices
11.1. Appendix 1–Atrial Fibrillation
Guideline 2017–2018: Prioritised Clinical
Questions for External Literature Review
1. Do patients with CHA2DS2-VASc 1 benefit from long-
term anticoagulation?
2. Does the addition of biomarkers (troponin, BNP, cystatin
C, D-dimer, CRP and interleukin 6) to CHA2DS2-VASc
improve the predictive ability of the score?
3. Does point-of-care INR measurement improve outcomes
in Australian patients with atrial fibrillation receiving
warfarin?
4. What is the persistence to risk factor control and what
interventions have been shown to improve this?
5. What is the persistence and adherence to atrial fibrillation
drugs (rhythm control and anticoagulants) and what
interventions have been shown to improve this?
BNP, B-type natriuretic peptide; CRP, C-reactive protein;
INR, international normalised ratio.
11.2. Appendix 2–Abbreviations and
Acronyms
AAD Antiarrhythmic drug
ACS Acute coronary syndrome
AF Atrial fibrillation
AHRE Atrial high-rate episode
APTT Activated partial thromboplastin time
ARISTOTLE Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation
trial
ARTESiA Apixaban for the Reduction of Thrombo-
Embolism in Patients with Device-detected
sub-clinical Atrial Fibrillation trial
AUGUSTUS trial Apixaban Versus Vitamin K Antagonist in
Patients With Atrial Fibrillation and Acute
Coronary Syndrome and/or Percutaneous
Coronary Intervention
AV Atrioventricular
AVR Aortic valve replacement
BAFTA Birmingham Atrial Fibrillation Treatment of
the Aged
BMI Body mass index
BNP B-type natriuretic peptide
BP Blood pressure
bpm Beats per minute
BRIDGE Bridging Anticoagulation in Patients Who
Require Temporary Interruption of Warfarin
Therapy for an Elective Invasive Procedure
or Surgery trial
CAA Cerebral amyloid angiopathy
CABANA Catheter Ablation vs Anti–arrhythmic Drug
Therapy for Atrial Fibrillation
CABG Coronary artery bypass graft
CAST Chinese Acute Stroke Trial
CHD Congenital heart disease
CI Confidence interval
CIED Cardiac implanted electrical device
CKD Chronic kidney disease
COMPARE-AF Role of Coumadin in Preventing
Thromboembolism in Atrial Fibrillation (AF)
Patients Undergoing Catheter Ablation
CPAP Continuous positive airway pressure
CrCl Creatinine clearance
CRYSTAL AF Continuous Cardiac Monitoring to Assess
Atrial Fibrillation After Cryptogenic Stroke
study
CSANZ Cardiac Society of Australia and New
Zealand
CTI Cavotricuspid isthmus
DAPT Dual antiplatelet therapy
EAST-AFNET-4 Early Treatment of Atrial Fibrillation for
Stroke Prevention Trial, Atrial Fibrillation
Network trial
ECG Electrocardiogram
EGM Atrial electrocardiogram
ESUS Embolic stroke of uncertain source
EWOLUTION Design of a Registry to Evaluate Real-world
Clinical Outcomes in Patients with AF and
High Stroke Risk-treated with the
WATCHMAN Left Atrial Appendage
Closure Technology register
FEIBA Factor eight inhibitor bypassing activity
GI Gastrointestinal
GIT Gastrointestinal tract
GP General practitioner
GRADE Grading of Recommendations Assessment,
Development and Evaluation
GUCH Grown-up patients with congenital heart
disease
HCM Hypertrophic cardiomyopathy
HR Hazard ratio
ICH Intracranial haemorrhage
ICM Implanted cardiac monitor
INR International normalised ratio
IST International Stroke Trial
LA Left atrial
LAA Left atrial appendage
LMWH Low molecular weight heparin
LQTS Long QT syndrome
LV Left ventricle
LVOT Left ventricular outflow tract
MRI Magnetic resonance imaging
NAVIGATE ESUS Rivaroxaban Versus Aspirin in Secondary
Prevention of Stroke and Prevention of
Systemic Embolism in Patients With Recent
Embolic Stroke of Undetermined Source
NHFA National Heart Foundation of Australia
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NOAC Non-vitamin K oral anticoagulant
NOAH-AFNET 6 Non-vitamin K Antagonist Oral
Anticoagulants in Patients with Atrial High
Rate Episodes trial
N-VAF Non-valvular atrial fibrillation
OAC Oral anticoagulant
OR Odds ratio
PCC Prothrombin complex concentrate
PIONEER AF-PCI Open-label, Randomized, Controlled,
Multicenter Study Exploring Two Treatment
Strategies of Rivaroxaban and a Dose-
adjusted Oral Vitamin K Antagonist
Treatment Strategy in Subjects with Atrial
Fibrillation who Undergo Percutaneous
Coronary Intervention trial
PT Prothrombin time
QALY Quality-adjusted life year
RACE Rate Control Versus Electrical Cardioversion
for Persistent Atrial Fibrillation trial
RACE II Rate Control Efficacy in Permanent Atrial
Fibrillation: A Comparison Between Lenient
Versus Strict Rate Control II trial
RCT Randomised clinical trial
RE-CIRCUIT Randomized Evaluation of Dabigatran
Etexilate Compared to Warfarin in
Pulmonary Vein Ablation: Assessment of an
Uninterrupted Periprocedural
Anticoagulation Strategy trial
RE-DUAL PCI Randomized Evaluation of Dual
Antithrombotic Therapy with Dabigatran
Versus Triple Therapy with Warfarin in
Patients with Nonvalvular Atrial Fibrillation
Undergoing Percutaneous Coronary
Intervention trial
RE-LY Randomized Evaluation of Long-Term
Anticoagulation Therapy
RE-VERSE AD Reversal Effects of Idarucizumab on Active
Dabigatran study
ROCKET AF Rivaroxaban Once Daily, Oral, Direct Factor
Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation
SAPT Single antiplatelet therapy
THANZ Thrombosis & Haemostasis Society of
Australia and New Zealand
TIA Transient ischaemic attack
TOE Transoesophageal echocardiography
TSH Thyroid stimulating hormone
TT Thromboplastin time
UFH Unfractionated heparin
WOEST What is the Optimal Antiplatelet and
Anticoagulant Therapy in Patients with
Oral Anticoagulation and Coronary Stenting
trial
VENTURE-AF Study Exploring Two Treatment Strategies
in Patients with Atrial Fibrillation Who
Undergo Catheter Ablation Therapy
11.3. Appendix 3–Online Register of
Conflicts of Interest
Available at: https://www.heartfoundation.org.au/
for-professionals/clinical-information/atrial-fibrillation
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